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ABSTRACT
Objectives: The aim of this systematic review is to
appraise the evidence for the use of anti-VEGF
drugs and steroids in diabetic macular oedema (DMO)
as assessed by change in best corrected visual
acuity (BCVA), central macular thickness and adverse
events
Data source: MEDLINE, EMBASE, Web of Science
with Conference Proceedings and the Cochrane Library
(inception to July 2012). Certain conference abstracts
and drug regulatory web sites were also searched.
Study eligibility criteria, participants and
interventions: Randomised controlled trials were
used to assess clinical effectiveness and observational
trials were used for safety. Trials which assessed
triamcinolone, dexamethasone, fluocinolone,
bevacizumab, ranibizumab, pegaptanib or aflibercept in
patients with DMO were included.
Study appraisal and synthesis methods: Risk of
bias was assessed using the Cochrane risk of bias tool.
Study results are narratively described and, where
appropriate, data were pooled using random effects
meta-analysis.
Results: Anti-VEGF drugs are effective compared to
both laser and placebo and seem to be more effective
than steroids in improving BCVA. They have been
shown to be safe in the short term but require frequent
injections. Studies assessing steroids (triamcinolone,
dexamethasone and fluocinolone) have reported mixed
results when compared with laser or placebo. Steroids
have been associated with increased incidence of
cataracts and intraocular pressure rise but require
fewer injections, especially when steroid implants are
used.
Limitations: The quality of included studies varied
considerably. Five of 14 meta-analyses had moderate
or high statistical heterogeneity.
Conclusions and implications of key findings:
The anti-VEGFs ranibizumab and bevacizumab have
consistently shown good clinical effectiveness without
major unwanted side effects. Steroid results have been
mixed and are usually associated with cataract
formation and intraocular pressure increase. Despite
the current wider spectrum of treatments for DMO,
only a small proportion of patients recover good vision
(≥20/40), and thus the search for new therapies needs
to continue.
INTRODUCTION
Diabetic macular oedema (DMO) is a com-
plication of diabetic retinopathy and a
leading cause of blindness. The prevalence
of DMO is likely to increase with more
people suffering from diabetes.1 Increasing
DMO has signiﬁcant implications for
patients, healthcare providers and wider
society. Laser has been the mainstay of treat-
ment, but recently antivascular endothelial
growth factor (anti-VEGF) drugs and steroids
have been introduced as potential alterna-
tives to laser photocoagulation.
Burden of disease
Diabetic retinopathy is present at the time of
diagnosis of diabetes mellitus in 0–30% of
individuals.2 The incidence is estimated to
be 2.3/100 person-years for the overall dia-
betic population and 4.5 for patients on
insulin therapy.3 There is good evidence that
progression to DMO is associated with
ARTICLE SUMMARY
Article focus
▪ To review the evidence for triamcinolone, dexa-
methasone, fluocinolone, bevacizumab, ranibizu-
mab, pegaptanib and aflibercept in the treatment
of diabetic macular oedema.
Key messages
▪ The anti-VEGFs ranibizumab and bevacizumab
have consistently shown good clinical effective-
ness in the short term without major unwanted
side effects.
▪ Steroid results have been mixed and are usually
associated with cataract formation and IOP
increase.
Strengths and limitations of this study
▪ A robust, detailed review of the literature has
been undertaken and, when appropriate, data
have been combined in meta-analysis.
▪ The quality of studies included varied
considerably.
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duration of disease,4–7 poor glycaemic control8 and, in
type 2 diabetes, the need for insulin,9 though the need
for insulin therapy is more a marker for duration and
poor control.
The number of people with DMO is likely to increase
as diabetes becomes more common. Some reports have
suggested a decrease in progression to severe visual loss
between 1975–1985 and 1986–2008 in a combined popu-
lation of types 1 and 2.10 Regular screening for retinop-
athy and better glycaemic control are thought to have
reduced the progression to severe visual loss. Diabetic
retinopathy is associated with a reduced quality of life.
Compared with all diabetic complications, blindness was
perceived to be the third worst health state after a major
stroke and amputation.11
In the USA, the presence of DMO at diagnosis is asso-
ciated with 29% additional costs within the ﬁrst 3 years
compared with individuals without retinopathy at diag-
nosis.12 In 2010, the estimated healthcare costs for DMO
in England were £92 million, with £65.6 million being
spent on hospital treatment and related costs.13
Visual impairment results in increased welfare costs,
early retirement and costs of home help and carers.14 In
England in 2010 (total population 52.23 million), the
estimated population with diabetes was 2.34 million; the
above social costs were estimated to be £11.6 million for
DMO.13
Overview of pathophysiology
DMO is caused mainly by disruption of the blood-retinal
barrier. The complex pathway that leads to this disruption
has been previously described in this journal.15 Sustained
hyperglycaemia causes a multifactorial cascade of physio-
logical processes, involving increased permeability, cytokine
activation, altered blood ﬂow, hypoxia and inﬂammation.
Vascular endothelial growth factor-A (VEGF-A) is a major
contributor to the inﬂammatory process and, in particular,
to angiogenesis and permeability.16 Hypoxia caused by
microvascular disease stimulates the release of VEGF-A to
aid perfusion. There are six major isoforms of VEGF-A:
121, 145, 165, 183, 189 and 206. In addition to causing
widespread microvascular injury, there is now evidence that
hyperglycaemia results in preceding neuronal dysfunction,
which may contribute to visual loss.17
Overview of current treatments
Laser photocoagulation has been the mainstay of treat-
ment for DMO. The landmark Diabetic Retinopathy
Study18 and the Early Treatment Diabetic Retinopathy
Study (ETDRS)19 20 demonstrated its clinical effective-
ness. However, although laser photocoagulation was
clearly effective in preserving vision, it was less successful
in restoring it, once lost. Furthermore, patients with
perifoveal ischaemia are not amenable to this form of
therapy. In EDTRS, although laser was shown to reduce
the risk of moderate visual loss (a loss of three ETDRS
lines) by 50%, visual acuity improved in only 3% of
patients.20 However, in some recent trials, laser has
improved the proportion of patients with more than or
equal to 10 letters by 7–31%.21–24 In addition, laser is
not without side effects. Foveal burns, visual ﬁeld
defects, retinal ﬁbrosis and laser scars have been
reported.25 Over the following decade it became appar-
ent that certain patients suffered severe visual loss
despite aggressive treatment.26
Steroids and anti-VEGF drugs are newer treatments in
DMO. Intravitreal corticosteroids have potent anti-
inﬂammatory effects. Triamcinolone (Kenalog) is not
licensed for eye use but has been used to treat DMO for
over 10 years. Triamcinolone (Trivaris), recently, was
licensed for eye use. The development of intravitreal
implants has allowed sustained release formulations.
Fluocinolone acetonide (Iluvien, Alimera Sciences) and
dexamethasone (Ozudex, Allergan) are implants that
have been introduced recently.
Anti-VEGF agents have shown efﬁcacy compared with
laser. Bevacizumab (Avastin, Genenetch/Roche) is a
monoclonal antibody that targets all VEGF isoforms.
Although being developed for colorectal cancer, it is
widely used off-label, as an intravitreal treatment for
macular oedema of different aetiologies. Ranibizumab
(Lucentis, Genentech/Roche) is a fragment of the beva-
cizumab antibody (molecular weight of ranibizumab
48.4 KDa compared with 149 KDa for bevacizumab). It
was designed speciﬁcally for use in the eye. Ranibizumab
is considerably more expensive than bevacizumab (the
estimated cost of ranibizumab is $2000/dose compared
with $50 for bevacizumab).27 Pegaptanib (Macugen,
Eyetech Pharmaceuticals/Pﬁzer) is a PEGylated aptamer,
with a high afﬁnity to the VEGF isoform 165, and was
approved for the treatment of exudative AMD in 2004.
Aﬂibercept (Regeneron/Bayer HealthCare) is a recent
addition to the anti-VEGF class that targets all forms of
VEGF-A and placental growth factor.
Aim of the review
The aim of this review is to provide clinicians with an
up-to-date overview of current intraocular drug treat-
ments for DMO. It is hoped that the information con-
tained herein will assist clinicians to present their patients
with the best evidence supporting each treatment, includ-
ing possible complications. In addition, this review may
be helpful to policy makers. The review focuses on the
current evidence for the use of anti-VEGF drugs and ster-
oids to treat DMO, as assessed by change in best cor-
rected visual acuity (BCVA) (mean and proportion with
more than two lines improvement), central macular
thickness (CMT), as determined by optical coherence
tomography (OCT), and their adverse events.
EVIDENCE ACQUISITION
A systematic literature search was performed. The data-
bases searched included MEDLINE, EMBASE, Web of
Science with Conference Proceedings and the Cochrane
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Library. The dates searched were from the inception of
each database until July 2012.
The search terms combined the following key words:
ranibizumab or lucentis or bevacizumab or avastin or
pegaptanib or macugen or aﬂibercept or vegf trap-eye
or steroid* or corticosteroid* or dexamethasone or ﬂuo-
cinolone or triamcinolone or anti-VEGF* or anti-
vascular endothelial growth factor*
AND
DMO or diabetic macular edema or diabetic retinopathy
or diabetic maculopathy
AND
(masked or sham or placebo OR control group or
random*) OR (systematic review or meta-analysis) OR
(risk or safety or adverse or harm or pharmacovigilance
or side-effect* or precaution* or warning* or contraindi-
cation* or contra-indication* or tolerability or toxic)
The meeting abstracts of the Association for Research
in Vision and Ophthalmology, the American Diabetes
Association (2002–2012) and the European Association
for the Study of Diabetes were searched from 2002 to
2012.
In addition, the web sites of the European Medicines
Agency and the US Food and Drug Association were
searched for data on registration status and safety.
Clinicaltrials.gov and the EU Clinical Trials Register were
searched in July 2012 for data on ongoing research.
Full details of the searches are shown in appendix 1.
Randomised controlled trials (RCT) were used to
evaluate clinical effectiveness. Safety was assessed
through both RCTs and observational studies.
RCTs were included provided that they (1) addressed
the use of triamcinolone, dexamethasone, ﬂuocinolone,
bevacizumab, ranibizumab, pegaptanib or aﬂibercept in
patients with DMO, (2) had a minimum follow-up of
6 months and (3) had a minimum of 25 eyes per study
arm. Studies were excluded if they (1) evaluated laser
only, (2) assessed the effect of the aforementioned treat-
ments in macular oedema due to other retinal diseases
(instead of DMO), (3) used only a single dose, (4) were
combined with a surgical intervention or (5) published
studies in languages other than English. There were no
exclusions based on drug dose. Trials were excluded if
they evaluated combined drug treatment with surgery or
systemic treatment.
Search results were screened by two independent
authors ( JF and PR/DS). Data were extracted by one
author (CC) and checked by a second ( JF). Data
extracted included inclusion/exclusion criteria, baseline
demographics, BCVA expressed as a change in logMAR/
ETDRS letters or proportion of participants with more
than two or three lines BCVA improvement, CMT and
adverse events. Risk of bias was assessed using the
Cochrane risk of bias tool.
Studies were assessed for similarity in study popula-
tion, interventions (dose and frequency), outcomes and
time to follow-up, with a view to including similar studies
in a meta-analysis. Conference abstracts were excluded
from the meta-analysis because their quality and detailed
methodology were not clear. A difference of 6 months
was allowed between study follow-ups because of the
potential heterogeneity from disease progression and
differences in the number of doses prescribed. If salient
data were not reported, such as SDs, data were sought by
personal communication with authors. Data were ana-
lysed using Review Manager software. If data from mul-
tiple time-points were available, the primary end-point
data were used. Data were entered by one author ( JF)
and double-checked by a second (DS). Mean differences
were calculated for change in BCVA and CMT and ORs
were calculated for proportion of participants with more
than two lines improvement. The 95% CIs were calcu-
lated for all outcomes. Statistical heterogeneity was mea-
sured through I2 scores. A score of less than 30% was
considered as low heterogeneity, a score of more than
70% was considered as high heterogeneity and scores
between 30% and 70% were considered as moderate.
A random effects model was used throughout. The
random effects model assumes variability between
studies and therefore models uncertainty into the
meta-analysis. Fixed assumes no variability. Generally
speaking, the random effects model results in wider CIs.
RESULTS
The literature search identiﬁed 430 unique articles for
possible inclusion, as shown in ﬁgure 1. In total, 328 arti-
cles were excluded on the basis of title and abstract,
leaving 102 full papers to be read. Fifty-one of these arti-
cles were excluded; the reasons for their exclusion are
summarised in table 1. Fifty-one articles from 29 studies
met the inclusion criteria and were included in the
review; these are described in tables 3–16. Seven studies
were suitable for meta-analysis.
Study quality
The quality of the included studies was, in general, good
as is shown in table 2. (Note that the meeting abstracts
were not quality assessed, owing to the lack of details
reported on the methods.) Most studies adequately
described sequence generation, except in three studies
where it was unclear.28–30 However, allocation conceal-
ment was poorly described throughout, with only eight
reports addressing this issue appropriately.31–38
Reporting of masking also varied. A number of studies
masked patients using sham injection or sham
laser.21 24 29 31 33 36 38 39 40 Various studies reported that
masking of patients was impossible. Assessors, where
reported, were masked. In two studies, incomplete out-
comes were not addressed.31 41 Baseline characteristics
were consistent within study treatment arms.
Administration of laser followed the ETDRS protocol, or
a modiﬁed version, in all studies that described laser
administration.21–24 28 30 33 34 42 43 Two studies, both
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available only as meeting abstracts, did not report the
laser administration details.44 45
Intravitreal anti-VEGFs
The characteristics of all published studies including
design, inclusion/exclusion criteria, intervention, out-
comes and their timing are shown in tables 3–8. Safety
data for each drug are shown in tables 9–16.
Ranibizumab
Nine RCTs have evaluated ranibizumab as a potential
new treatment for patients with DMO (tables 3 and 8);
seven were sponsored by industry, and two were led by
independent investigators)(table 7).21 46 READ-2 was the
ﬁrst large RCT (n=126).28 47 It compared ranibizumab
(0.5 mg) alone, and ranibizumab in combination with
laser and laser alone. At 6 months, BCVA had improved
signiﬁcantly in the ranibizumab alone group compared
with laser alone or ranibizumab plus laser. Addition of
laser to ranibizumab did not provide additional BCVA
gain. REVEAL (n=396) compared ranibizumab (0.5 mg)
with ranibizumab plus laser and laser alone.48 At
12 months, both ranibizumab arms resulted in a statistic-
ally signiﬁcantly better improvement in BCVA compared
to laser alone. The addition of laser did not confer
further beneﬁt.
Within the past 2 years, the results of RESOLVE,36
RESTORE24 and RISE and RIDE38 have been published
in peer-reviewed journals. RESTORE (n=345) rando-
mised similar groups as the READ-2 study (ranibizumab
(0.5 mg) alone, laser alone and ranibizumab plus laser);
outcomes were evaluated at 12 months. Ranibizumab
improved mean BCVA, with laser providing no additional
beneﬁt. Two-year extended follow-up suggested that
these results continued.49 RESOLVE (n=151) compared
two doses of ranibizumab (0.3 and 0.5 mg) with sham
injection. The greatest improvement in BCVA at
12 months was in the 0.3 mg group (11.8 letter gain)
compared to the 0.5 mg group (8.8 letter gain) or sham
injection (1.4 letter loss). In this study, rescue laser was
Figure 1 PRISMA flow diagram.
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allowed after 3 months of treatment, if BCVA had
decreased by 10 letters or more, or if the investigator con-
sidered the macula not to be ﬂat as assessed by OCT.
Only 4.9% of the ranibizumab group required rescue
laser, compared with 34.7% in the sham injection group.
READ-2 and RESTORE were suitable for pooling
through meta-analysis and, when doing so, it was found
that ranibizumab statistically signiﬁcantly improved mean
BCVA compared with laser (ﬁgure 2). In regard to the pro-
portion of patients gaining more than or equal to 15
letters, individual trials showed a statistically signiﬁcant dif-
ference between laser and ranibizumab but when these
two trials were pooled using a random effects model, the
result was no longer statistically signiﬁcant. When a ﬁxed
effects model was used, the result was statistically signiﬁcant
(ﬁgure not shown). Adding laser to ranibizumab did not
add any signiﬁcant beneﬁt (ﬁgure 3). In fact, the mean
change in BCVA and the proportion of patients with more
than 15 letter gain favoured, although not statistically sig-
niﬁcantly so, ranibizumab alone compared with ranibizu-
mab plus laser. This was probably a chance effect.
RISE (n=377) and RIDE (n=382) were identical in
design. The study arms are similar to those in the
RESOLVE study, 0.3 or 0.5 mg ranibizumab compared
with sham. In the RISE study, the proportion of patients
with 15 or more letter gain was greatest in the 0.3 mg
group at 24 months, whereas in the RIDE study this was
greatest in the 0.5 mg group. In the DRCRN trial
(n=854), Elman and colleagues compared ranibizumab
(0.5 mg) plus prompt (within 3–10 days post ranibizu-
mab) or deferred (≥24 weeks) laser with sham injection
plus prompt laser, or triamcinolone (4 mg, Trivaris) plus
prompt laser (table 8). At 1 year, both ranibizumab
groups reported greater gains in mean BCVA change
than triamcinolone or laser alone. Interestingly, at
2 years (n=628), the proportion of patients with 10 or
more letter gain was not statistically signiﬁcantly differ-
ent between ranibizumab plus prompt laser and laser
alone groups, but was statistically signiﬁcant in the rani-
bizumab plus deferred laser compared with laser alone
comparison. The reason for this is not clear.
READ-3 (n=152) has been published in abstract form
and compared monthly injections of intravitreal ranibi-
zumab high dose (2.0 mg) and low dose (0.5 mg).50 At
6 months, there was no statistically signiﬁcant difference
in BCVA between groups.
One study (n=63), published in abstract form, was
identiﬁed which directly compared monthly injections
of ranibizumab (0.5 mg) with bevacizumab (1.5 mg).51
At 48 weeks, the authors found no statistically signiﬁcant
difference between bevacizumab and ranibizumab.
RESTORE, READ-2 and DRCRN (12 month data used)
were suitable for pooling through meta-analysis to compare
ranibizumab plus laser and laser alone (ﬁgure 4).
Ranibizumab plus laser resulted in a statistically signiﬁ-
cantly greater change in mean BCVA, proportion of
patients with more than 15 letter gain and CMT reduction
versus laser alone.
Table 1 List of excluded studies
Study Reason
Active comparator trials
Cho et al87 Single dose
DRCRN 2010
(Googe et al)88
<6 months f/u
Faghihi et al89 Single dose
Figueroa et al90 Single dose
Isaac et al91 Single dose
Paccola et al92 Single dose
Prager et al93 <25 pts per arm
Ozturk et al94 Non-RCT
Marey and Ellakwa95 <6 months
Shahin and El-Lakkany96 Single dose
Pegaptanib
Loftus et al97 Quality of life data
Ranibizumab
Ferrone and Jonisch98 <25 pts per arm
Bevacizumab
Solaiman et al99 Single dose
DRCRN—Scott et al100 <25 pts per arm
Lee101 Non-RCT
Isaac et al91 Single dose
Trimacinolone
Audren et al102 Single dose (dosing study)
Audren et al103 Single dose
Avitabile104 Mixed RVO and DMO
Bandello et al105 Case report+PDR
Bonini et al106 Single dose injection technique
Cellini et al107 Single injection PSTI
Cardillo et al108 Single injection PSTI
Chung et al109 Single injection PSTI
Dehghan et al110 Single dose
DRCRN—Chew et al 111 <25 pts per arm
Gil et al112 <25 pts per arm
Entezari et al113 <6 months
Hauser et al114 Single dose
Jonas et al115 Single dose
Joussen et al116 Study protocol
Avci and Kaderli117 Anaesthetic technique
Kang et al118 Single dose
Kim et al119 Single injection and CME
Lam et al120 Single injection
Lee121 Single injection
Maia et al122 Single dose
Massin et al123 Single dose
Mohamed et al124 Post hoc analysis
Nakamura et al125 Single dose
Spandau et al126 Single dose
Tunc127 <6 months
Verma et al128 Single dose
Wickremasinghe et al129 Single dose
Yalcinbayir et al130 Single dose
Dexamethasone
Haller et al131 <6 months
Haller et al132 <25 pts per arm
Kuppermann et al 133 Mixture of macular oedema
causes
Boyer et al134 Non-randomised
Fluocinolone
Campochiaro et al135 <25 pts per arm
Diclofenac
Elbendary71 <35 pts per arm
CME, cystoid macular edema; DMO, diabetic macular oedema
PDR, proliferative diabetic retinopathy; PSTI, posterior subtenon
injection; RVO, retinal vein occlusion.
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Table 2 Study quality
Study (author
and year)
Adequate
sequence
generation
Allocation
concealment Masking
Incomplete
outcome data
addressed
Free of
selective
reporting
Free of other bias
(eg, similarity at
baseline, power
assessment) Funder
Anti-VEGFs
Ranibizumab
READ-2 Study28 47 Unclear Unclear Unclear Yes (91.3%
completion)
Yes Comparison groups
similar at baseline;
power analysis not
mentioned
Juvenile Diabetes
Research Foundation,
Genentech Inc
RESOLVE Study
(Massin et al)36
Yes Yes Yes (patients and
outcome assessors)
Yes (82%
completion in
sham arm,
90.2% with
ranibizumab)
Yes Comparison groups
similar at baseline;
power analysis unclear
Novartis Pharma,
Switzerland
RESTORE Study
(Mitchell et al)24
Yes Unclear Yes (patients,
outcome assessors)
Yes
(87.3–88.3%
completion)
Yes Comparison groups
similar at baseline;
power analysis carried
out (power adequate
for VA changes)
Novartis Pharma,
Switzerland
RISE and RIDE
(Nguyen et al)38
Yes Yes Yes (patients, treating
physician masked to
assigned dose of
ranibizumab)
Yes (2 year
study completed
by 83.3% of
patients in RISE
and by 84.6% in
RIDE)
Yes Comparison groups
similar at baseline; ITT
analysis; power
analysis carried out
(power adequate for
primary endpoint)
Genentech Inc
Bevacizumab
BOLT Study
(Michaelides
et al)23 52
Yes Unclear Partial (outcome
assessors, not
patients)
Yes (97.5%
completion)
Yes Comparison groups
similar at baseline
(except laser group
had longer duration of
clinically significant
DMO); power analysis
carried out (power
adequate for VA
changes)
Moorfields Special
Trustees, National Institute
for Health Research
Faghihi et al53 Yes Unclear Yes (patient Yes (100%
completion)
Yes Comparable groups at
baseline
Not specified
Lam et al35 Yes Yes Yes (patients and
technicians assessing
BCVA, OCT and IOP)
Yes (92.3%
follow-up at
6 months)
Yes Comparison groups
similar at baseline;
power analysis carried
out (power adequate
for CMT changes)
Supported in part by the
Action for Vision Eye
Foundation Hong Kong
(charity)
Continued
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Table 2 Continued
Study (author
and year)
Adequate
sequence
generation
Allocation
concealment Masking
Incomplete
outcome data
addressed
Free of
selective
reporting
Free of other bias
(eg, similarity at
baseline, power
assessment) Funder
Pegaptanib
Cunningham et al/
Adamis et al39 57
Yes Unclear Yes (patients and
outcome assessors)
Yes (95%
completion)
Yes Comparison groups
similar at baseline;
acknowledge lack of
power to detect
differences between
doses of pegaptanib
Eyetech Pharmaceuticals
Inc, New York, and Pfizer
Inc, New York
Sultan et al40 Yes Unclear Yes (patients and
outcome assessors)
Yes
(69.9–73.8%
completion)
Yes Comparison groups
similar at baseline;
power analysis carried
out (power adequate
for VA changes)
Pfizer Inc, New York
Aflibercept
Da Vinci et al30 58 Unclear
(predetermined
randomisation
scheme)
Unclear Yes (patients) Yes (85%
completion)
Yes Comparison groups
similar at baseline,
power calculation
completed
Regeneron
Pharmaceuticals, Inc,
New York
Steroids
Dexamethasone
Haller et al59 Yes Unclear Yes (patients to
dexamethasone dose,
outcome assessors)
Yes (92%
completion)
Yes Comparison groups
similar at baseline;
power analysis carried
out, but study not
powered to detect
differences in
subgroups
Oculex Pharmaceuticals
Inc
Fluocinolone
FAME Study
(Campochiaro et al)29 60
Unclear Unclear Partial (patients,
masking of outcome
assessment not
mentioned)
Yes
(drop-out rate
19.0–22.7%)
Yes Comparison groups
similar at baseline;
power analysis not
mentioned
Alimera Sciences Inc,
Atlanta, Georgia; Psivida
Inc, Watertown,
Massachusetts
Pearson et al43 Yes Unclear Third party masked
design (patient and
investigator not
masked)
No losses to
follow-up
Yes Demographic
characteristics were
similar between implant
and SOC groups;
power calculation done,
study adequately
powered
Bausch & Lomb Inc,
Rochester, New York
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Table 2 Continued
Study (author
and year)
Adequate
sequence
generation
Allocation
concealment Masking
Incomplete
outcome data
addressed
Free of
selective
reporting
Free of other bias
(eg, similarity at
baseline, power
assessment) Funder
Triamcinolone
DRCR Network
2008 22 61 63 64
Yes Unclear Partial (patients to
triamcinolone dose,
outcome assessors
not formally masked
but generally not
aware of participant’s
study group)
Yes (81–86%
completion)
Yes Comparison groups
similar at baseline;
power analysis carried
out (power adequate
for VA changes)
Cooperative agreement
from the National Eye
Institute, National Institute
of Diabetes and Digestive
and Kidney Diseases,
National Institutes of
Health, Department of
Health and Human
Services
Gillies et alSutter
et al32 136–138
Yes Yes Yes (patients,
outcome assessors)
Yes (91%
completion
intervention,
83% control)
Yes Comparison groups
similar at baseline (but
limited demographic
data); power analysis
carried out (power
adequate for VA
changes)
Sydney Eye Hospital
Foundation and Juvenile
Diabetes Research
Foundation, New York
Gillies et al33 Yes Yes Yes (patients,
outcome assessors)
Yes (84.5%
completion)
Yes Power analysis carried
out (power adequate
for VA changes)
National Health and
Medical Research
Council, Canberra,
Australia, and the Sydney
Eye Hospital Foundation
Sydney, Australia
Lam et al34 Yes Yes Partial (outcome
assessors)
No losses to
follow-up
Yes Comparison groups
similar at baseline;
power analysis carried
out (power adequate
for CMT changes)
Action for Vision
Foundation, Hong Kong
Ockrim et al/
Sivaprasad et al42 62
Yes Unclear Unclear Yes (94%
completion)
Yes Comparison groups
similar at baseline;
power analysis carried
out (power adequate
for VA changes)
Special Trustees of
Moorfields Eye Hospital
Continued
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Table 2 Continued
Study (author
and year)
Adequate
sequence
generation
Allocation
concealment Masking
Incomplete
outcome data
addressed
Free of
selective
reporting
Free of other bias
(eg, similarity at
baseline, power
assessment) Funder
Active comparator trials
Ahmadieh et al31 Yes Yes Yes (patients and
outcome assessors)
Unclear Yes CMT lower in control
group at baseline
(p<0.05), other
baseline values similar;
power analysis carried
out (power adequate
for CMT changes)
Not reported
DRCR Network 21 46 Yes Unclear Yes (patients, except
deferred laser group;
outcome assessors);
masking discontinued
after the first year
Yes (1 year
completion for
91–95% of
eyes)
Yes Comparison groups
similar at baseline;
power analysis carried
out (power adequate
for VA changes)
Cooperative agreement
from the National Eye
Institute, National Institute
of Diabetes and Digestive
and Kidney Diseases,
National Institutes of
Health and Human
Services; Ranibizumab
provided by Genentech,
triamcinolone provided by
Allergan Inc; companies
also provided funds to
defray the study’s clinical
site costs
Lim et al55 Yes Unclear Yes (investigators
only)
Yes (7.5% drop
out after
enrolment)
Yes Groups similar at
baseline. The
bevacizumab group
received more
injections
Not reported
Soheilian et al37 41 Yes Yes Yes (patients and
outcome assessors)
Unclear
(36 week
completion for
76–88%)
Yes CMT significantly lower
and VA significantly
better in MPC group at
baseline, other
baseline values similar;
power analysis carried
out (power adequate
for VA changes)
Ophthalmic Research
Centre, Labbafinejad
Medical Center, Tehran
MPC, macular photocoagulation.
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Table 3 Ranibizumab trials
Study Participants and baseline values Intervention
Outcome (change
from baseline at
study end)
READ-2 Study (Nguyen
et al)28 47 USA
Multicenter
Design: 3-arm RCT
Follow-up: 6 months, 2-year
extension (no relevant
outcomes as IVR received by
all groups by that time, no
safety outcomes for 2-year
data)
N: 126 eyes of 126 patients
Inclusion criteria: ≥18 years, type 1
or 2 DM, DMO, BCVA 20/40-20/
320, CMT ≥250 µm, HbA1c ≥6%
within 12 months before
randomisation; expectation that
scatter laser photocoagulation not
required for 6 months
Exclusion criteria: contributing
causes to reduced BCVA other
than DMO, focal/grid laser within
3 months, intraocular steroid within
3 months, intraocular VEGF
antagonist within 2 months
Age: 62 years
Sex: 52–69% female
Diabetes type: not reported
HbA1c: 7.39–7.77%
Baseline VA: ETDRS letter score
24.85–28.35
Baseline CMT: excess foveal
thickness 198.75–262.52 µm
Comorbidities: not reported
Group 1 (IVR, n=42 eyes): IV
injections of 0.5 mg ranibizumab at
baseline, 1, 3 and 5 months
Group 2 (L, n=42 eyes): focal/grid
laser at baseline and 3 months if
CMT ≥250 µm
Group 3 (IVRL, n=42 eyes): IV
injections of 0.5 mg ranibizumab at
baseline and 3 months, followed by
focal/grid laser treatment 1 week
later
Regimen for all groups: after
6 months, patients could receive IV
injections of ranibizumab no more
than every 2 months or focal/grid
laser no more than every 3 months
if CMT ≥250 µm
Laser Modified ETDRS protocol
was used
At 6 months
BCVA (ETDRS):
BCVA (letters) p Value
IVR +7.24 0.0003 vs L
L −0.43
IVRL +3.80 NS vs IVR or
L
Plus ≥3 lines
IVR 22% <0.05 vs L
L 0
IVRL 8%
CMT (OCT):
CMT (µm) p Value
IVR −106.3 All <0.01 vs
baseline, NS for
elimination of ≥50%
excess foveal
thickness between
groups
L −82.8
IVRL −117.2
READ-3 Study (Do et al) USA50
Design: phase 2, 2-arm RCT
Follow-up: 6 months
N: 152 eyes
Inclusion criteria: NR
Exclusion criteria: NR
Age: NR
Sex: NR
Diabetes type: NR
HbA1c: NR
Baseline VA: Mean BCVA Snellen
equivalent 20/63 in the 2.0 mg
group and 20/80 in the 0.5 mg
group
Baseline CST (central subfield
thickness): 432 µm in the 2.0 mg
group and 441 µm in the 0.5 mg
group
Comorbidities: NR
Group 1 (IVR2.0, n=NR): monthly
injections
Group 2 (IVR0.5, n=NR): monthly
injections
After month 6, eyes evaluated and
additional ranibizumab injections
given on an as needed basis if
DMO still present on OCT.
At 6 months:
BCVA
Mean BCVA
letters gain
p Value
IVR2.0 +7.46 NR
IVR0.5 +8.69 NR
CST CST reduction
IVR2.0 −163.86 µm NR
IVR0.5 −169.27 µm NR
Continued
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Table 3 Continued
Study Participants and baseline values Intervention
Outcome (change
from baseline at
study end)
RESOLVE Study (Massin
et al)36
Multicenter international
Design: 3-arm
placebo-controlled RCT
Follow-up: 12 months
N: 151 eyes of 151 patients
Inclusion criteria: >18 years, type 1
or 2 DM, clinically significant DMO,
BCVA 20/40–20/160, HbA1c <12%,
decreased vision attributed to
foveal thickening from DMO, laser
photocoagulation could be safely
withheld in the study eye for at
least 3 months after randomisation
Exclusion criteria: unstable medical
status, panretinal laser
photocoagulation performed within
6 months before study entry,
previous grid/laser
photocoagulation except patients
with only mild laser burns at least
1000 µm from the centre of the
fovea performed >6 months
previously
Age: 63–65 (range 32–85) years
Sex: 43.1–49% female
Diabetes type: 96.1–98% type 2
DM
HbA1c: 7.3–7.6 (range 5.3–11.1) %
Baseline VA: ETDRS letter score
59.2–61.2 SD9.0–10.2
Baseline CMT: 448.9–459.5
SD102.8–120.1 µm
Comorbidities: not reported
Group 1 (IVR0.3, n=51 eyes):
0.3 mg (0.05 ml) IV ranibizumab,
3 monthly injections (dose up to
0.6 mg, see below)
Group 2 (IVR0.5, n=51 eyes):
0.5 mg IV (0.05 ml) ranibizumab,
3 monthly injections (dose up to
1.0 mg, see below)
Group 3 (C, n=49 eyes): sham
treatment, 3 monthly injections
Regimen for all groups: after month
1, the injection dose could be
doubled if CMT remained >300 µm
or was >225 µm and reduction in
retinal oedema from previous
assessment was <50 µm; once
injection volume was 0.1 ml it
remained that for subsequent
injections; if treatment had been
withheld for >45 days, subsequent
injections restarted at 0.05 ml;
68.6% of dose doubling with
ranibizumab, 91.8% with sham;
34.7% of rescue laser
photocoagulation in sham group,
4.9% in ranibizumab group
At 12 months
BCVA (ETDRS):
BCVA (letters) p Value
IVR0.3 +11.8 SD6.6 <0.0001 vs C
IVR0.5 +8.8 SD11.0 <0.0001 vs C
C −1.4 SD14.2
Change ≥10 letters
IVR0.3 Gain 72.5%
loss 0
<0.0001 vs C
IVR0.5 Gain 49%
loss 9.8%
0.001 vs C
C Gain 18.4%
loss 24.5%
CMT (OCT):
CMT (µm) p Value
IVR0.3 −200.7 SD122.2 <0.0001 vs C
IVR0.5 −187.6 SD147.8 <0.0001 vs C
C −48.4 SD153.4
RESTORE Study (Mitchell
et al)24 49
N: 345 eyes of 345 patients
Inclusion criteria: ≥18 years, type 1
Group 1 (IVR, n=116 eyes): 0.5 mg
IV ranibizumab plus sham laser
At 12 months
BCVA (ETDRS):
Continued
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Table 3 Continued
Study Participants and baseline values Intervention
Outcome (change
from baseline at
study end)
Multicenter international
Design: 3-arm RCT
Follow-up: 12 months
or 2 DM, HbA1c ≤10%, visual
impairment due to DMO (eligible for
laser treatment), stable medication
for management of diabetes, BCVA
ETDRS letter score 39–78
Exclusion criteria: concomitant eye
conditions that could affect VA,
active intraocular inflammation or
infection, uncontrolled glaucoma in
either eye, panretinal laser
photocoagulation within 6 months
or focal/grid laser photocoagulation
within 3 months prior to study entry,
history of stroke, hypertension
Age: 62.9–64.0 SD8.15–9.29 years
Sex: 37.1–47.7% female
Diabetes type: 86.4–88.8% type 2
DM
HbA1c: not reported
Baseline VA: ETDRS letter score
62.4–64.8 SD9.99–11.11
Baseline CMT: 412.4–426.6
SD118.01–123.95
Comorbidities: not reported
(median injections 7 (range 1–12),
median sham laser treatments 2
(range 1–5))
Group 2 (IVRL, n=118 eyes):
0.5 mg IV ranibizumab plus active
laser (median injections 7 (range
2–12), median laser treatments 1
(range 1–5))
Group 3 (L, n=111 eyes): laser
treatment plus sham injections
(median sham injections 7 (range
1–12), median laser treatments 2
(range 1–4))
Regimen for all groups: 3 initial
monthly injections, followed by
retreatment schedule; 1 injection
per month if stable VA not reached;
Laser retreatments in accordance
with ETDRS guidelines at intervals
no shorter than 3 months from
previous treatment
BCVA (letters) p Value
IVR +6.1 SD6.43 <0.0001 vs L
IVRL +5.9 SD7.92 <0.0001 vs L
L +0.8 SD8.56
BCVA change categories
IVR Plus ≥10: 37.4%
Loss ≥10: 3.5%
<0.0001 vs L
IVRL Plus ≥10: 43.2%
Loss ≥10: 4.2%
<0.0001 vs L
L Plus ≥10: 15.5%
Loss ≥10: 12.7%
CMT (OCT):
CMT (µm) p Value
IVR −118.7
SD115.07
0.0002 vs L
IVRL −128.3
SD114.34
<0.0001 vs L
L −61.3 SD132.29
REVEAL Study (Ohji and
Ishibashi )48
Japan Multicenter
Design: phase III
double-masked RCT
Follow-up: 12 months
N: 396 patients
Inclusion criteria: NR
Exclusion criteria: NR
Age: 61.1 years
Sex: NR
Diabetes type: 98.7% with type 2
diabetes
HbA1c: 7.5%
Baseline VA: 58.6 letters
Baseline CMT: 421.9 µm
Comorbidities: NR
Group 1 (IVR 0.5 + sham laser,
n=133): day 1, month 1, 2 and
pro-renata thereafter based on
BCVA
Group 2 (IVR 0.5+ active laser,
n=132): day 1, month 1, 2 and
pro-renata thereafter based on
BCVA
Group 3 (sham injection + active
laser, n=131): day 1, month 1, 2
and pro-renata thereafter based on
BCVA
Active/sham laser photocoagulation
performed according to ETDRS
guidelines at ≥3 month intervals
At 12 months
BCVA:
Mean average
change from
baseline to
months 1–12
p Value
IVR+sham laser +5.9 vs laser <0.0001
IVR+laser +5.7 vs laser <0.0001
Laser+sham +1.4
Mean change
from baseline to
month12 in
BCVA and CRT
IVR+sham laser +6.6; −148.0 µm vs C <0.0001
IVR+laser +6.4; −163.8 µm vs C <0.0001
Laser+sham +1.8; −57.1 µm
Continued
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Table 3 Continued
Study Participants and baseline values Intervention
Outcome (change
from baseline at
study end)
RISE Study (Brown et al/
Nguyen et al)38 139
USA
Multicenter
Design: 3-arm double-blind
sham-controlled RCT
Follow-up: 24 months
N: 377 eyes of 377 patients
Inclusion criteria: ≥18 years, type 1
or 2 diabetes, BCVA 20/40–20/320,
DMO CMT ≥275 µm
Exclusion criteria: prior vitreoretinal
surgery, recent history (within
3 months of screening) of
panretinal or macular laser in the
study eye, intraocular
corticosteroids or antiangiogenic
drugs, those with uncontrolled
hypertension, uncontrolled diabetes
(HbA1c >12%), recent (within
3 months) cerebrovascular accident
or myocardial infarction
Age: 61.7–62.8 SD8.9–10.0 (range
21–87) years
Sex: 41.6–48% female
Diabetes type: type 1 or 2
HbA1c: 7.7% SD 1.4–1.5; ≤8%
(65–68.3%); >8% (31.7%–35%)
Baseline VA: Mean ETDRS letter
score 54.7–57.2; ≤20/200
(7.9–13.6%); >20/200 but
<20/40 (72.4–72.8%); ≥20/40
(13.6–19.7%)
Baseline CMT: 463.8–474.5 µm
Comorbidities: History of smoking
46.4–51.2%
Group 1 (IVR0.3, n=125 eyes):
0.3 mg IV ranibizumab
Group 2 (IVR0.5, n=125 eyes):
0.5 mg IV ranibizumab
Group 3 (C, n=127 eyes): sham
injection
Regimen for all groups: monthly
injections; need for macular rescue
laser assessed monthly starting at
month 3
At 24 months
BCVA:
Plus ≥15 letters p Value
IVR0.3 44.8% <0.0001 vs C
IVR0.5 39.2% =0.0002 vs C
C 18.1%
Loss of <15
letters
IVR0.3 97.6% =0.0086 vs C
IVR0.5 97.6% =0.0126 vs C
C 89.8%
Snellen
equivalent of
20/40 or better
IVR0.3 60% <0.0001 vs C
IVR0.5 63.2% <0.0001 vs C
C 37.8%
Mean BCVA
gain (letters)
IVR0.3 +12.5 SD14.1 <0.0001 vs C
IVR0.5 +11.9 SD12.1 <0.0001 vs C
C +2.6 SD13.9
CFT:
Mean change
from baseline
p Value
IVR0.3 −250.6 SD212.2 <0.0001 vs C
IVR0.5 −253.1 SD183.7 <0.0001 vs C
C −133.4 SD209.0
RIDE study (Boyer et al/
Nguyen et al)38 140
USA
Multicentre
Design: 3-arm double-blind
sham-controlled RCT
Follow-up: 24 months
N: 382 eyes
Inclusion criteria: ≥18 years, type 1
or 2 diabetes, BCVA 20/40–20/320
and DMO CMT ≥275 µm
Exclusion criteria: prior vitreoretinal
surgery, recent history (within
3 months of screening) of
Group 1 (IVR0.3, n=125 eyes):
0.3 mg IV ranibizumab
Group 2 (IVR0.5, n=127 eyes):
0.5 mg IV ranibizumab
Group 3 (C, n=130 eyes): sham
injection
Regimen for all groups: Patients
At 24 months
BCVA:
More than 15
letters
p Value
IVR0.3 33.6% <0.0001 vs C
IVR0.5 45.7% <0.0001 vs C
C 12.3%
Continued
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Table 3 Continued
Study Participants and baseline values Intervention
Outcome (change
from baseline at
study end)
panretinal or macular laser in the
study eye, intraocular
corticosteroids or antiangiogenic
drugs, those with uncontrolled
hypertension, uncontrolled diabetes
(HbA1c >12%), recent (within
3 months) cerebrovascular accident
or myocardial infarction
Age: 61.8–63.5 (range 22–91)
years
Sex: 37–49.1% female
Diabetes type: type 1 or 2
HbA1c: 7.6 SD1.3–1.5; ≤8%
(65.8–67.5%); >8% (32.5–34.2%)
Baseline VA: Mean ETDRS letter
score 56.9–57.5
Baseline CMT: 447.4–482.6 µm
Comorbidities: history of smoking
33.6–51.6%
were eligible for rescue macular
laser starting at month 3
Less than 15
letters
IVR0.3 1.6% >0.05 vs C
IVR0.5 3.9% <0.05 vs C
C 8.5%
Snellen
equivalent of
20/40 or better
IVR0.3 54.4% =0.0002 vs C
IVR0.5 62.2% <0.0001 vs C
C 34.6%
Mean BCVA gain (letters)
IVR0.3 +10.9 SD10.4 <0.0001vs C
IVR0.5 +12.0 SD14.9 <0.0001 vs C
C +2.3 SD14.2
CMT:
Mean change
from baseline
p Value
IVR0.3 −259.8 SD169.3 <0.0001 vs C
IVR0.5 −270.7 SD201.6 <0.0001 vs C
C −125.8 SD198.3
Injections are intravitreal unless otherwise noted. BCVA, best corrected visual acuity; C, control; CMT, central macular thickness; CSME, clinically significant macular oedema; DDS,
dexamethasone; DIL, dexamethasone followed by laser; DM, diabetes mellitus; DMO, diabetic macular oedema; DP, diastolic pressure; DR, diabetic retinopathy; HR QoL, health-related quality
of life; IOP, intraocular pressure; IV, intravitreal; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib; IVR, intravitreal ranibizumab; IVT, intravitreal triamcinolone; IVTL, intravitreal
triamcinolone plus laser; IVVTE, intravitreal VEGF Trap Eye; L, laser; MLT/MPC, macular laser therapy/macular photocoagulation; NEI VFQ-25, National Eye Institute Visual Function
Questionnaire-25; NPDR, non-proliferative diabetic retinopathy; NR, not reported; OCT, optical coherence tomography; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation;
RCT, randomised controlled trial; SOC, standard of care; SP, systolic pressure; SRFA, fluocinolone; VA, visual acuity; VEGF, vascular endothelia growth factor.
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Table 4 Bevacizumab studies
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
BOLT Study
(Michaelides
et al/Rajendram
et al))23 52 85
UK
Design: 2-arm
RCT
Follow-up:
12 months
N: 80 eyes of 80 patients
Inclusion criteria: ≥18 years, type 1 or 2 DM, BCVA in
the study eye 35–69 ETDRS letters at 4 m (≥6/60 or
≤6/12), center-involving clinically significant DMO with
CMT ≥270 µm; media clarity, papillary dilation and
cooperation sufficient for adequate fundus imaging; a
least 1 prior macular laser therapy; IOP <30 mm Hg;
fellow eye BCVA ≥3/60; fellow eye received no
anti-VEGF in past 3 months and no expectation of
such therapy
Exclusion criteria: (ocular for study eye) macular
ischemia, macular oedema due to causes other than
DMO, coexistent ocular disease affecting VA or DMO,
any treatment for DMO in prior 3 months, PRP within
3 months prior to randomisation or anticipated, PDR,
HbA1c >11%, medical history of chronic renal failure;
any thromboembolic event within 6 months prior to
randomisation, unstable angina, evidence of active
ischemia on ECG; major surgery within 28 days of
randomisation or planned; participation in an
investigational drug trial; systemic anti-VEGF or
pro-VEGF treatment within 3 months of enrolment;
pregnancy, lactation; intraocular surgery within
3 months of randomisation; aphakia; uncontrolled
glaucoma; significant external ocular disease
Age: 64.2 SD8.8 years
Sex: 31% female
Diabetes type: 90% type 2 DM, 10% type 1 DM
HbA1c: 7.5–7.6 SD1.2–1.4%
Baseline VA: ETDRS letter score 54.6–55.7
SD8.6–9.7
Baseline CMT: 481–507 SD121–145 µm
Comorbidities: 19% mild NPDR (level 35), 46%
moderate NPDR (level 43), 19% moderately severe
NPDR (level 47), 13% severe NPDR (level 53), 3%
moderate PDR (level 65), 79–88% phakic
Group 1 (MLT, n=38 eyes):
modified ETDRS macular laser
therapy; reviewed every
4 months up to 52 weeks;
retreatment performed if clinically
indicated by ETDRS guidelines
(median 4 laser treatments)
Group 2 (IVB, n=42 eyes):
1.25 mg (0.05 ml) IV
bevacizumab at baseline, 6 and
12 weeks; subsequent IVB
injections (up to 52 weeks)
guided by an OCT-based
retreatment protocol (median 13
injections)
Laser modified ETDRS protocol,
retreatment by ETDRS
guidelines
At 24 months
BCVA (ETDRS):
BCVA.
mean (SD)
p Value
MLT −0.5 (10.6)
IVB +8.6 (9.1) 0.005 vs
MLT
BCVA gain categories
(letters)
MLT gaining
≥10: 7%
losing >15:
4%
IVB gaining
≥10: 49%
losing >15:
32%
0.001 vs
MLT
0.004 vs
MLT
CMT (µm,
quartiles)
p Value
MLT −118
SD171
IVB −146
SD122
0.62 vs
MLT
Lam et al35
Hong Kong
Design: 2-arm
RCT
N: 52 eyes of 52 patients
Inclusion criteria: ≥18 years, type 1 or 2 DM, clinically
significant DMO (slit-lamp biomicroscopy, ETDRS
criteria; leakage confirmed by fluorescein
Group 1 (IVB1.25, n=26 eyes):
1.25 mg bevacizumab (0.05 ml)
Group 2 (IVB2.5, n=26 eyes):
2.5 mg bevacizumab (0.1 ml)
At 6 months
BCVA (ETDRS chart):
Continued
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Table 4 Continued
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
Follow-up:
6 months
angiography, CMT ≥250 µm on OCT), BCVA ≥1.3
ETDRS logMAR units; only patients with diffuse DMO
recruited
Exclusion criteria: macular oedema due to reasons
other than diabetes, significant media opacities,
macular ischemia of ≥1 disk area, vitreomacular
traction, PDR, aphakia, glaucoma or ocular
hypertension, previous anti-VEGF treatment,
intraocular surgery except uncomplicated cataract
extraction (but > 6 months prior), focal DMO, any laser
procedure within previous 4 months, subtenon or
intravitreal triamcinolone injection within 6 months,
pregnancy
Age: 65.3 SD8.9 years
Sex: 46.2% female
Diabetes type: not reported
HbA1c: 7.5 SD1%
Baseline VA: 0.61 SD0.29 logMAR
Baseline CMT: 466 SD127 µm
Comorbidities: not reported
Regimen for all groups:
3 monthly IV injections, topical
0.5% levofloxacin 4×/day for up
to 2 weeks after each injection
BCVA (logMAR) p Value
IVB1.25 0.11
SD0.31
(+5.5
letters)
0.018 vs
baseline,
NS vs
IVB2.5
IVB2.5 0.13
SD0.26
(+6.5
letters)
0.003 vs
baseline
CMT (OCT) CMT (µm) p Value
IVB1.25 96 0.002 vs
baseline,
NS vs
IVB2.5
IVB2.5 74 0.013 vs
baseline
Subgroups:
▸ For patients with previous
DMO treatment (mainly laser):
no significant reduction in
CMT at 6 months (452 µm at
baseline to 416 µm at
6 months, p=0.22); no
significant improvement in
BCVA (0.66 logMAR at
baseline to 0.56 logMAR at
6 months (+5 letters),
p=0.074)
Continued
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Table 4 Continued
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
Faghihi et al53
Iran
Design: 2-arm
RCT
Follow-up:
6 months
N: 80 eyes of 40 patients
Inclusion criteria: Bilateral non-tractional CSME,
10/10> V.A≥1/10, Controlled blood pressure.
Exclusion criteria: Advanced or advanced active PDR,
significant cataract, glaucoma, history of recent
vascular accident (eg, MI, CVA), Previous treatment of
CSME or PDR, or pharmacotherapy for CSME,
macular ischemia and uncontrolled hypertension
Age: 57.7±8 years
Sex: 27.5% females
Diabetes type: NR
HbA1c: 8.42±1.82 g/dl
Baseline VA: 0.326–0.409 (SD 0.279–0.332)
Baseline CMT: 277 um–287 um (SD 78–98)
Comorbidities: not reported
Group 1 (IVB, n=40 eyes):
1.25 mg bevacizumab
Group 2 (IVB+MPC, n=40 eyes):
1.25 mg bevacizumab
Regimen for all groups: Eyes
examined every 2 months and if
evidence of CSME IVB was
injected. Mean of the number of
IVB injections in IVB group and
IVB+MPC group were 2.23±1.24
and 2.49±1.09, respectively
At 6 months
Mean change in BCVA (ETDRS
chart):
BCVA
(logMAR)
p Value
IVB 0.138 <0.05 vs
baseline
IVB+MPC 0.179 <0.05 vs
baseline
▸ no statistically significant
difference between the two
groups
CMT (OCT):
CMT (µm) p Value
IVB −39 <0.05 vs
baseline
IVB+MPC −39 <0.05 vs
baseline
▸ No statistically significant
difference between the two
groups
BCVA, best corrected visual acuity; C, control; CMT, central macular thickness; CSME, clinically significant macular oedema; DDS, dexamethasone; DIL, dexamethasone followed by laser; DM,
diabetes mellitus; DMO, diabetic macular oedema; DP, diastolic pressure; DR, diabetic retinopathy; HR QoL, health-related quality of life; IOP, intraocular pressure; IV, intravitreal; IVB,
intravitreal bevacizumab; IVP, intravitreal pegaptanib; IVR, intravitreal ranibizumab; IVT, intravitreal triamcinolone; IVTL, intravitreal triamcinolone plus laser; IVVTE, intravitreal VEGF Trap Eye; L,
laser; MLT/MPC, macular laser therapy/macular photocoagulation; NEI VFQ-25, National Eye Institute Visual Function Questionnaire-25; NPDR, non-proliferative diabetic retinopathy; NR, not
reported; OCT, optical coherence tomography; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation; RCT, randomised controlled trial; SOC, standard of care; SP, systolic
pressure; SRFA, fluocinolone; VA, visual acuity; VEGF, vascular endothelia growth factor.
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Table 5 Pegaptanib and aflibercept studies
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
Pegaptanib
Cunningham et al/
Adamis et al39 57
USA
Design: 4-arm phase
II RCT
Follow-up: 36 weeks
N: 172 eyes of 172 patients
Inclusion criteria: ≥18 years, type 1 or 2 DM, DMO
involving the center of the macula with corresponding
leakage from microaneurysms, retinal telangiectasis,
or both; clear ocular media, BCVA letter scores
between 68 and 25 in the study eye and at least 35 in
the fellow eye; IOP ≤23 mm Hg, focal
photocoagulation could be safely deferred for
16 weeks; no ECG abnormalities, no major serological
abnormalities
Exclusion criteria: history of panretinal or focal
photocoagulation; neodymium:yttrium–aluminum–
garnet laser or peripheral retinal cryoablation in
previous 6 months; any ocular abnormality interfering
with VA assessment or fundus photography;
vitreoretinal traction; vitreous incarceration; retinal vein
occlusion involving the macula; atrophy/scarring/
fibrosis or hard exudates involving the center of the
macula; history of intraocular surgery within previous
12 months, myopia of ≥8 diopters, axial length of
≥25 mm, likelihood of requiring panretinal
photocoagulation within following 9 months; cataract
surgery within 12 months; active ocular or periocular
infection; previous therapeutic radiation to the eye,
head, or neck; known serious allergies to fluorescein
dye; HbA1c ≥13%, pregnancy
Age: 61.3–64.0 SD9.3–10.1 years
Sex: 45–55% female
Diabetes type: 5–10% IDDM
HbA1c: 7.1–7.7 SD1.2–1.6
Baseline VA: letter score 55.0–57.1 SD9.1–11.5
Baseline CMT: 423.2–476.0 µm
Comorbidities: not reported
Group 1 (IVP0.3, n=44
eyes): 0.3 mg IV
pegaptanib (90 µl) (median
5 injections (range 1–6))
Group 2 (IVP1, n=44 eyes):
1 mg IV pegaptanib (90 µl)
(median 6 injections
(range 3–6))
Group 3 (IVP3, n=42 eyes):
3 mg IV pegaptanib (90 µl)
(median 6 injections (range
1–6))
Group 4 (C, n=42 eyes):
sham injection (median 5
injections (range 1–6))
Regimen for all groups:
injections at baseline, week
6 and week 12; thereafter,
additional injections
administered every 6 weeks
at the discretion of the
investigators if judged
indicated (maximum of 6
injections up to week 30);
laser photocoagulation
allowed after week 13 if
judged indicated by the
study-masked
ophthalmologist (25% for
IVP0.3, 30% for IVP1, 40%
for IVP3, 48% for C)
At 36 weeks
BCVA:
BCVA (letters) p Value
IVP0.3 +4.7 0.04 vs C
IVP1 +4.7 0.05 vs C
IVP3 +1.1 NS vs C
C −0.4
Plus ≥10 letters
IVP0.3 34% 0.003 vs C
IVP1 30%
IVP3 14%
C 10%
CMT (OCT):
CMT
(µm, 95% CI)
p Value
IVP0.3 −68.0 (−118.9 to
−9.88)
0.02 vs C
IVP1 −22.7 (−76.9 to
+33.8)
NS vs C
IVP3 −5.3 (−63.0 to
+49.5)
NS vs C
C +3.7
▸ Subgroups: of 16
participants with retinal
neovascularisation at
baseline, 8 of 13 (62%) in
the pegaptanib groups and
0 of 3 in the sham group
had regression of
neovascularisation at
36 weeks
Continued
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Table 5 Continued
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
Sultan et al40
Multicenter
international
Design: 2-arm
placebo-controlled
RCT
Follow-up: 2 years
(primary efficacy
endpoint at 1 year)
N: 260 eyes of 260 patients
Inclusion criteria: ≥18 years, type 1 or 2 DM, DMO
involving the center of the macula not associated with
ischemia, CMT ≥250 µm, BCVA letter score 65–35,
IOP ≤21 mm Hg, clear ocular media
Exclusion criteria: any abnormality other than DMO
affecting VA assessment, vitreomacular traction;
yttrium–aluminium–garnet laser, peripheral retinal
cryoablation, laser retinopexy for retinal tears, focal or
grid photocoagulation within prior 16 weeks; panretinal
photocoagulation <6 months before baseline or likely
to be needed within 9 months; significant media
opacities; intraocular surgery in prior 6 months;
pathological high myopia; prior radiation in region of
study eye; history of severe cardiac or peripheral
vascular disease, stroke in prior 12 months, major
surgery in prior 1 month, treatment in prior 90 days
with any investigational agent or with bevacizumab for
any nonocular condition, HbA1c ≥10% or signs of
uncontrolled diabetes, hypertension, known relevant
allergies; pregnant or lactating
Age: 62.3–62.5 SD9.3–10.2 years
Sex: 39–46% female
Diabetes type: 6.3–7.5% type 1 DM, 92.5–93.7% type
2 DM
HbA1c: 42.5–45.9% <7.6%, 54.1–57.5% >7.6%
Baseline VA: letter score 57.0–57.5 SD8.1–8.9
Baseline CMT: 441.6–464.6 SD135.5–148.5 µm
Comorbidities: not reported
Group 1 (IVP, n=133 eyes):
0.3 mg IV pegaptanib
sodium (mean number of
injections 12.7 SD4.6)
Group 2 (C, n=127 eyes):
sham injection (mean
number of injections 12.9
SD4.4)
Regimen for all groups:
injections every 6 weeks up
to week 48 (9 injections); at
investigator determination
(ETDRS criteria), laser
photocoagulation could be
performed at week 18, with
possible repeat treatment at
a minimum of 17 weeks
later (maximum 3
treatments per year) (laser
treatments in 25.2% of IVP
group and 45% of C
group); in year 2, injections
as judged necessary
At 1 year
BCVA (ETDRS): BCVA (letters) p Value
IVP +5.2 <0.05 vs C
C +1.2
Plus ≥10 letters
IVP 36.8% 0.0047 vs C
C 19.7%
Retinopathy:
Increase in degree by ≥2 steps
IVP 4.1% 0.047 vs C
C 12.4%
Decrease in degree by ≥2 steps
IVP 10.2% NS vs C
C 3.1%
CMT (OCT): Decrease in CMT
IVP ≥25%: 31.7%
≥50%: 14.6%
NS vs C
C ≥25%: 23.7%
≥50%: 11.9%
At 2 years
BCVA (ETDRS):
BCVA (letters) p Value
IVP +6.1 <0.01 vs C
C +1.3
Plus ≥10 letters
IVP 38.3% NS vs C
C 30%
Retinopathy:
Increase in degree by ≥2 steps
IVP 6.3% NS vs C
C 13.8%
Decrease in degree by ≥2 steps
IVP 16.3% 0.03 vs C
C 3.8%
CMT (OCT):
Decrease in CMT
IVP ≥25%: 40.4%
≥50%: 19.2%
NS vs C
C ≥25%: 44.6%
≥50%: 26.1%
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Table 5 Continued
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
QoL:
▸ NEI VFQ-25: between
group differences not
significant at 54 weeks; at
102 weeks, significantly
greater improvement in
composite score and
subscales distance vision
activities, social
functioning and mental
health with pegaptanib
▸ EQ-5D: no significant
differences between
groups in EQ-5D scores at
weeks 54 or 102
Aflibercept
DA VINCI 2010 (Do
et al)30 58
Multicenter
Design: 5-arm phase
II RCT
Follow-up: 24 weeks
N: 221 eyes of 221 patients
Inclusion criteria: aged >18 years and diagnosed with
type 1 or 2 diabetes mellitus, with DMO involving the
central macula defined as CRT (>250 um in the
central subfield. Participants were required to have
BCVA letter score at 4 m of 73–24. Women of
childbearing potential were included only if they were
willing to not become pregnant and to use a reliable
form of birth control during the study period
Exclusion criteria: history of vitreoretinal surgery;
panretinal or macular laser photocoagulation or use of
intraocular or periocular corticosteroids or
antiangiogenic drugs within 3 months of screening;
vision decrease due to causes other than DMO;
proliferative diabetic retinopathy (unless regressed and
currently inactive); ocular inflammation; cataract or
other intraocular surgery within 3 months of screening,
laser capsulotomy within 2 months of screening;
aphakia; spherical equivalent of >8 diopters; or any
concurrent disease that would compromise visual
acuity or require medical or surgical intervention
during the study period: active iris neovascularisation,
vitreous hemorrhage, traction retinal detachment, or
preretinal fibrosis involving the macula; visually
significant vitreomacular traction or epiretinal
Trial of VEGF Trap-Eye
(VTE), randomised on a
1 : 1:1 : 1:1 basis
Group 1 (IVVTE1, n=44
eyes): IVVTE, 0.5 mg every
4 weeks
Group 2 (IVVTE2, n=44
eyes): IVVTE, 2 mg every
4 weeks
Group 3 (IVVTE3, n=42
eyes): IVVTE, 2 mg for 3
initial months then every
8 weeks
Group 4 (IVVTE4, n=45
eyes): IVVTE, 2 mg for 3
initial months then as
needed
Group 5 (L, n=44 eyes):
laser photocoagulation
Laser modified ETDRS
protocol
At 6 months
BCVA (letters) p Value
IVVTE1 +8.6 0.005 vs L
IVVTE2 +11.4 <0.0001 vs L
IVVTE3 +8.5 0.008 vs L
IVVTE3 +10.3 0.0004 vs L
L +2.5
plus ≥10 letters
IVVTE1 50% NR
IVVTE2 64% NR
IVVTE3 43% NR
IVVTE3 58% NR
L 32% NR
CMT(um)
IVVTE1 −144.6 0.0002 vs L
IVVTE2 −194.5 <0.0001 vs L
IVVTE3 −127.3 0.007 vs L
IVVTE3 −153.3 <0.0001 vs L
L −67.9
At 12 months
BCVA (letters) p Value
IVVTE1 +11.0 ≤0.0001 vs L
IVVTE2 +13.1 ≤0.0001 vs L
IVVTE3 +9.7 ≤0.0001 vs L
IVVTE3 +12.0 ≤0.0001 vs L
Continued
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Table 5 Continued
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
membrane evident biomicroscopically or on OCT;
history of idiopathicor autoimmune uveitis; structural
damage to the center of the macula that is likely to
preclude improvement in visual acuity after the
resolution of macular oedema; uncontrolled glaucoma
or previous filtration surgery; infectious blepharitis,
keratitis, scleritis, or conjunctivitis; or current treatment
for serious systemic infection: uncontrolled diabetes
mellitus; uncontrolled hypertension; history of cerebral
vascular accident or myocardial infarction within
6 months; renal failure requiring dialysis or renal
transplant; pregnancy or lactation; history of allergy to
fluorescein or povidone iodine; only 1 functional eye
(even if the eye met all other entry criteria); or an
ocular condition in the fellow eye with a poorer
prognosis than the study eye
Age: 60.7–64.0 years (SD 8.1–11.5)
Sex: % female 35.6–47.6%
Diabetes type: percentage of type 2, 88.6–97.7%
HbA1c: 7.85–8.10 (SD 1.71–1.94)
Baseline VA: 57.6–59.9 (SD 10.1–12.5)
Baseline CMT: 426.1–456.6 µm (SD 111.8–152.4)
Comorbidities: history of any cardiac disease was
twice as common in the VEGF Trap-Eye groups
compared with the laser group
L −1.3
Plus ≥15 letters
IVVTE1 40.9% 0.0031 vs L
IVVTE2 45.5% 0.0007 vs L
IVVTE3 23.8% 0.1608 vs L
IVVTE3 42.2% 0.0016 vs L
L 11.4%
Plus ≥10 letters
IVVTE1 57% 0.0031 vs L
IVVTE2 71% 0.0007 vs L
IVVTE3 45% 0.1608 vs L
IVVTE3 62% 0.0016 vs L
L
CMT(µm)
IVVTE1 −165.4 <0.0001 vs L
IVVTE2 −227.4 <0.0001 vs L
IVVTE3 −187.8 <0.0001 vs L
IVVTE3 −180.3 <0.0001 vs L
L −58.4
BCVA, best corrected visual acuity; C, control; CMT, central macular thickness; CSME, clinically significant macular oedema; DDS, dexamethasone; DIL, dexamethasone followed by laser; DM,
diabetes mellitus; DMO, diabetic macular oedema; DP, diastolic pressure; DR, diabetic retinopathy; HR QoL, health-related quality of life; IOP, intraocular pressure; IV, intravitreal; IVB,
intravitreal bevacizumab; IVP, intravitreal pegaptanib; IVR, intravitreal ranibizumab; IVT, intravitreal triamcinolone; IVTL, intravitreal triamcinolone plus laser; IVVTE, intravitreal VEGF Trap Eye; L,
laser; MLT/MPC, macular laser therapy/macular photocoagulation; NEI VFQ-25, National Eye Institute Visual Function Questionnaire-25; NPDR, non-proliferative diabetic retinopathy; NR, not
reported; OCT, optical coherence tomography; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation; RCT, randomised controlled trial; SOC, standard of care; SP, systolic
pressure; SRFA, fluocinolone; VA, visual acuity; VEGF, vascular endothelia growth factor.
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Table 6 Dexamethasone and fluocinolone studies
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
Dexamethasone
Callanan et alUSA44
Design: 2-arm RCT
Follow-up: 12 months
N: 253 eyes of 253 patients
Inclusion criteria: diffuse DMO, CMT ≥275 µm,
BCVA ≥34 and ≤70 letters
Exclusion criteria: not reported
Age: not reported
Sex: not reported
Diabetes type: not reported
HbA1c: not reported
Baseline VA: not reported
Baseline CMT: not reported
Comorbidities: not reported
Group 1 (DIL, n=126 eyes):
dexamethasone IV implant
followed by laser
photocoagulation after 1 month
(mean 1.6 implants; 78.6%
completion)
Group 2 (L, n=127 eyes): laser
alone (79.5% completion)
Regimen for all groups: if
needed, patients were retreated
with the dexamethasone implant
at months 6 or 9, and with laser
at months 4, 7 and 10; mean 2.2
laser treatments per patient
Laser protocol not reported
At 12 months
BCVA:
Plus ≥10
letters (%)
p Value
DIL 28 NS vs L
L 24
▸ Patients in DIL group had
significantly greater
increases in BCVA from
baseline than patients in
the laser group (p<0.05) at
months 1–9 only
CMT (OCT):
▸ Patients in DIL group had
significantly greater mean
reductions from baseline in
CMT at months 1 and 6
only (p<0.001)
Haller et al59
USA
Multicenter
Design: 3-arm RCT
Follow-up: 6 months
(180 days), primary
outcome 3 months
(90 days)
N: 171 eyes of 171 patients
Inclusion criteria: ≥12 years, DMO persisting for
≥90 days after laser treatment or medical
therapy, BCVA by ETDRS between 20/40 (67
letters) and 20/200 (35 letters) due to clinically
detectable DMO; analysis includes only eyes
with DMO associated with DR
Exclusion criteria: history of vitrectomy in the
study eye; use of systemic, periocular, or
intraocular steroids within 30 days of enrolment;
moderate or severe glaucoma in the study eye;
poorly controlled hypertension (SP >160 mm Hg
or DP >90 mm Hg); poorly controlled diabetes
(HbA1c >13%)
Age: 62.9–63.8 years SD10.2–12.0
Sex: 45.6–49.1% female
Diabetes type: not reported
HbA1c: 7.3–7.6%
Baseline VA: letter score 54.4–54.7
SD9.96–11.88
Baseline CMT: 417.5–446.5 µm SD123.7–155.9
Comorbidities: 19–21% prior cataract extraction
Group 1 (DDS350, n=57 eyes):
350 µg dexamethasone IV drug
delivery system, implanted into
the vitreous cavity
Group 2 (DDS700, n=57 eyes):
700 µg dexamethasone IV drug
delivery system, implanted into
the vitreous cavity
Group 3 (C, n=57 eyes): no
treatment
Regimen for all groups: eyes
demonstrating a VA loss of ≥5
letters could be treated with any
other therapy (including laser
photocoagulation and IV
triamcinolone) (n=4 with
photocoagulation or IV
triamcinolone in the C group,
n=2 in the DDS350 group, none
in the DDS700 group)
At 90 days
BCVA (ETDRS):
Plus ≥10
letters
p Value
DDS350 21% (graph) NS vs C
DDS700 33% 0.007 vs C
C 12%
CMT (OCT):
CMT (µm) p Value
DDS350 −42.57
SD95.96
NS
(p=0.07) vs
C
DDS700 −132.27
SD160.86
<0.001 vs
C
C +30.21
SD82.12
At 180 days
BCVA (ETDRS):
Plus ≥10
letters
p Value
DDS350 20% (graph) NS vs C
DDS700 33% (graph) NS vs C
C 23% (graph)
Continued
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Table 6 Continued
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
Fluocinolone
FAME Study
(Campochiaro et al/
Campochiaro et al)29 60
Multicenter
international
Design: 3-arm
placebo-controlled RCT
Follow-up: 24 months;
abstract with 36 month
outcomes
N: 956 eyes of 956 patients
Inclusion criteria: DMO, CMT ≥250 µm despite
at least 1 prior focal/grid macular laser
photocoagulation treatment, BCVA ETDRS letter
score between 19 and 68 (20/50–20/400)
Exclusion criteria: glaucoma, ocular
hypertension, IOP >21 mm Hg, taking IOP
lowering drops; laser treatment for DMO within
12 weeks of screening, any ocular surgery in
the study eye within 12 weeks of screening;
ocular or systemic steroid therapy; active ocular
infection; pregnancy
Age: 62.5 SD9.4 years
Sex: 40.6%
Diabetes type: 6.6% type 1 DM, 92% type 2
DM, 1.4% uncertain
HbA1c: 7.8 SD1.59%
Baseline VA: ETDRS letter score 53.4 SD12.23
Baseline CMT: 469.0 SD164.78 µm
Comorbidities: 47.1% cataract at baseline,
62.7–67.4% phakic
Group 1 (0.5, n=375 eyes):
intravitreal insert releasing
0.2 µg/day fluocinolone
acetonide (FA) (2, 3, or 4
treatments received by 21.3, 1.9
and 0.3%)
Group 2 (SRFA0.5, n=393 eyes):
intravitreal insert releasing
0.5 µg/day fluocinolone
acetonide (2, 3, or 4 treatments
received by 22.6, 2.5 and 0.3%)
Group 3 (C, n=185 eyes): sham
injection (2, 3, or 4 treatments
received by 19.5, 2.7 and 1.6%)
Regimen for all groups: patients
could receive rescue focal/grid
laser therapy any time after the
first 6 weeks for persistent
oedema (35.2–36.7% in FA
groups, 58.9% control group,
p<0.001); treatments were
allowed every 3 months for
persistent or recurrent oedema;
patients eligible for another FA
insert at 1 year if ≥5 letter
reduction in BCVA or >50 µm
CMT increase from best status
At 24 months
BCVA (ETDRS):
BCVA (letters) p Value
SRFA0.2 +4.4 0.02 vs C
SRFA0.5 +5.4 0.017 vs C
C +1.7
Plus ≥15
letters (%)
p Value
SRFA0.2 29 0.002
SRFA vs C
SRFA0.5 29
C 16
Subgroups:
▸ BCVA benefits only in
pseudophakic eyes
(cataract surgery before or
during the study), in phakic
eyes, BCVA letter score
was reduced by 5 (high
dose) and 9 (low dose)
from baseline at 24 months
CMT (optical coherence
tomography):
CMT (µm) p Value
SRFA0.2 −167.8 0.005 vs C
SRFA0.5 −177.1 <0.001 vs
C
C −111.3
▸ effect maintained at 36
months
At 36 months
Plus ≥15
letters
p Value
SRFA0.2/0.5 28.7% 0.018
SRFA vs C
C 18.9%
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Table 6 Continued
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
Pearson et al43
USA
Multicenter
Design: 2-arm RCT
Follow-up: 36 months
N: 196 patients
Inclusion criteria: persistent or recurrent
unilateral or bilateral DMO with retinal thickening
involving fixation of ≥1 disc area in size, ETDRS
visual acuity of ≥20 letters (20/400) to ≤68
letters (20/50) and ≥1 macular laser treatment in
the study eye more than 12 weeks prior to
enrolment
Exclusion criteria: Ocular surgery within
3 months prior to enrolment, uncontrolled IOP
within the past 12 months while on ≥1
antiglaucoma medication, IOP of ≥22 mm Hg at
screening while on ≥1 antiglaucoma medication,
peripheral retinal detachment in the area of
implantation or media opacity precluding
diagnosis of status in the study eye
Age: 61.4–62.7 years
Sex: 41.7–42% female
Diabetes type: 62.3–70% on insulin
HbA1c: not reported
Baseline VA: not reported
Baseline CMT: not reported
Comorbidities: not reported
Group 1 (SRFA, n=127): 0.5 mg
sustained release fluocinolone
acetonide intravitreal implant
Group 2 (SOC, n=69): standard
of care—either repeat laser or
observation
Laser ETDRS protocol
At 3 years
BCVA:
Gain ≥15
letters
p Value
SRFA 31% NS
SOC 20%
Loss ≥15
letters
SRFA 17% NS
SOC 14%
CMT:
Mean change
in baseline
CMT
p Value
SRFA −86 NS
SOC −110
BCVA, best corrected visual acuity; C, control; CMT, central macular thickness; CSME, clinically significant macular oedema; DDS, dexamethasone; DIL, dexamethasone followed by laser;
DM, diabetes mellitus; DMO, diabetic macular oedema; DP, diastolic pressure; DR, diabetic retinopathy; HR QoL, health-related quality of life; IOP, intraocular pressure; IV, intravitreal; IVB,
intravitreal bevacizumab; IVP, intravitreal pegaptanib; IVR, intravitreal ranibizumab; IVT, intravitreal triamcinolone; IVTL, intravitreal triamcinolone plus laser; IVVTE, intravitreal VEGF Trap Eye;
L, laser; MLT/MPC, macular laser therapy/macular photocoagulation; NEI VFQ-25, National Eye Institute Visual Function Questionnaire-25; NPDR, non-proliferative diabetic retinopathy; NR, not
reported; OCT, optical coherence tomography; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation; RCT, randomised controlled trial; SOC, standard of care; SP, systolic
pressure; SRFA, fluocinolone; VA, visual acuity; VEGF, vascular endothelia growth factor.
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Table 7 Triamcinolone studies
Study
Participants and baseline
values Intervention
Outcome (change from
baseline at study end)
DRCR Network 2008 (Ip
et al/Beck et al/Bressler
et al)22 61 63 64
USA
Multicenter
Design: 3-arm RCT
Follow-up: 2 years,
additional 3 year
follow-up
N: 840 eyes of 693 patients
Inclusion criteria: >18 years, type
1 or 2 DM, study eye: (1) BCVA
(E-ETDRS) between 24 and 73
(20/320 and 20/40), (2) retinal
thickening due to DMO involving
the center of the macula main
cause for visual loss, (3) CMT
≥250 µm, (4) no expectation of
scatter photocoagulation within
4 months
Exclusion criteria: any prior
treatment with IV corticosteroids,
peribulbar steroid injection within
prior 6 months, photocoagulation
for DMO within prior 15 weeks,
panretinal scatter
photocoagulation within prior
4 months, pars plana vitrectomy,
history of open-angle glaucoma
or steroid-induced
IOP elevation requiring
IOP-lowering treatment, and IOP
≥25 mm Hg
Age: 63 SD9 years
Sex: 49% female
Diabetes type: 95% type 2 DM,
5% type 1 DM
HbA1c: 7.9 SD1.8%
Baseline VA: ETDRS letter score
59 SD11 (∼20/63)
Baseline CMT: 24 SD130 µm
Comorbidities: 21%
pseudophakic, 2% ocular
hypertension, 7% mild NPDR,
13% moderate NPDR, 40%
moderately severe NPDR, 11%
severe NPDR, 23.5% mild to
moderate, 3% high risk PDR
Group 1 (IVT1, n=256 eyes):
1 mg IV triamcinolone
(3.5 treatments)
Group 2 (IVT4, n=254 eyes):
4 mg IV triamcinolone
(3.1 treatments)
Group 3 (L, n=330 eyes):
focal/grid photocoagulation
(2.9 treatments)
Regimen for all groups:
retreatment protocol: where
indicated, retreatment was
performed within 4 weeks
after the follow-up visit and no
sooner than 3.5 months from
the time of last treatment;
eyes were generally retreated
unless:
(1) little or no oedema
involving the center of the
macula present and CMT
≤225 µm, (2) VA letter score
≥79 (20/25 or better),
(3) substantial improvement in
macular oedema since last
treatment (eg, ≥50%
decrease in CMT), (4)
clinically significant adverse
effect from prior treatment,
(5) additional treatment
deemed futile (<5 letter
improvement in VA letter
score or lack of CMT
reduction) and (6) for laser
group, complete focal/grid
photocoagulation already
given, with no areas identified
for which additional treatment
was indicated
Laser Modified ETDRS
At 2 years
BCVA (E-ETDRS):
BCVA (letters) p Value
IVT1 −2 SD18 0.02 vs L
NS vs IVT4
IVT4 −3 SD22 0.002 vs L
L +1 SD17
BCVA gain categories
IVT1 +10 or more: 25%
+9 to −9: 50%
−10 – more: 26%
0.03 vs L, NS vs
IVT4
IVT4 +10 or more: 28%
+9 to −9: 44%
−10 or more: 28%
0.01 vs L
L +10 or more: 31%
+9 to −9: 50%
−10 or more: 19%
Subgroups:
▸ Similar results when
considering only pseudophakic
eyes or eyes with minimal
cataract no substantially
different results based on
baseline VA, baseline CMT,
history of focal/grid
photocoagulation for DMO
▸ 3 year results consistent with 2
year results for BCVA and
CMT
CMT (OCT):
CMT (µm) p Value
IVT1 −86 SD167 <0.001 vs L,
NS vs IVT4
IVT4 −77 SD160 <0.001 vs L
L −139 SD148
Progression of retinopathy:
2 years 3 years p Value
IVT1 29% 35%
IVT4 21% 30% <0.05 vs L
L 31% 37%
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Table 7 Continued
Study
Participants and baseline
values Intervention
Outcome (change from
baseline at study end)
protocol as used in prior
DRCR.net protocols
Gillies et al
Sutter et al 32 136–138
Australia
Design: 2-arm
placebo-controlled RCT
Follow-up: 2 years,
additional 3-year
follow-up
N: 69 eyes of 43 patients
Inclusion criteria: patients with
persistent (≥3 months after
adequate laser treatment) DMO
involving the central fovea,
BCVA in the affected eye ≤6/9
Exclusion criteria: uncontrolled
glaucoma, loss of vision due to
other causes, systemic treatment
with >5 mg prednisolone (or
equivalent) daily, intercurrent
severe systemic disease, any
condition affecting follow-up or
documentation
Age: 62.4–69.6
SD9.2–12.5 years
Sex: 52% female
Diabetes type: not reported
HbA1c: 7.63–8.28 SD1.12–1.41
Baseline VA: ETDRS letter score
60.5–61.3 SD11.9–13.2
Baseline CMT: 439–444
SD101–125 µm
Comorbidities: 25%
pseudophakic
Group 1 (IVT, n=34 eyes):
4 mg (0.1 ml) IV triamcinolone
acetonide (mean 2.6
injections over 2 years)
Group 2 (C, n=35 eyes):
placebo injection
(subconjunctival saline
injection) (mean 1.8 injections
over 2 years)
Regimen for all groups:
retreatment considered at
each visit as long as
treatments were at least
6 months apart (retreatment if
VA decreased ≥5 letters from
previous peak value and
persistent CMT >250 µm), if
no improvement after
4 weeks, further laser
treatment was applied (n=1
laser treatment in intervention
group, n=16 in placebo group,
p=0.0001)
Laser ETDRS protocol
At 2 years
BCVA (ETDRS):
BCVA (letters) p Value
IVT +3.1 0.01 vs C
C −2.9
CVA gain categories
IVT +10 or more: 21%
+9 to −9: 70%
−10 or more: 9%
0.013 vs C
C +10 or more: 12%
+9 to −9: 62%
−10 or more: 25%
CMT (OCT):
CMT (µm) p Value
IVT −125 0.009 vs C,
difference
between groups
59 µm (95% CI
15 to 104)
C −75
Continued
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Table 7 Continued
Study
Participants and baseline
values Intervention
Outcome (change from
baseline at study end)
Gillies et al33
Australia
Design: 2-arm RCT
Follow-up: 24 months
N: 84 eyes of 54 patients
Inclusion criteria: DMO involving
the central fovea, CMT ≥250 µm,
BCVA 17–70 letters (∼20/40–20/
400), laser treatment could be
safely delayed for 6 weeks
without significant adverse
effects
Exclusion criteria: uncontrolled
glaucoma, controlled glaucoma
but with a glaucomatous visual
field defect, loss of vision
resulting from other causes,
systemic treatment with >5 mg
prednisolone (or equivalent)
daily, retinal laser treatment
within 4 months, intraocular
surgery within 6 months,
concurrent severe systemic
disease, any condition affecting
follow-up or documentation
Age: 65.4–66.9 SD8.9–9.5 years
Sex: 38.1–47.6% female
Diabetes type: not reported
HbA1c: 7.81–8.02
SD1.44–1.63%
Baseline VA: letter score
55.2–55.5 SD11.3–12.5
Baseline CMT: 482.1–477.4
SD122.7–155.5 µm
Comorbidities: not reported
Group 1 (IVTL, n=42 eyes):
4 mg (0.1 ml) IV triamcinolone
acetonide followed by laser
treatment (at least 1
retreatment in 2nd year in
69%)
Group 2 (L, n=42 eyes): sham
injection followed by laser
treatment (at least 1
retreatment in 2nd year in
45%)
Regimen for all groups:
retreatment with injection
followed by laser at discretion
of chief investigator, with at
least 6 weeks between
treatments; no retreatment if:
(1) investigator considered the
macula nearly flat and CMT
<300 µm; (2) VA was ≥79
letters (20/25) or VA had
improved by ≥5 letters
compared with the best VA
after treatment or baseline
acuity; (3) laser treatment was
considered by the investigator
as inappropriate or had no
potential for improvement
At 24 months
BCVA (ETDRS):
BCVA (letters) p Value
ITL +0.76 NS vs L
L −1.49
BCVA gain
categories
IVTL +10 or more: 36%
+9 to −9: 31%
−10 or more: 33%
0.049 vs L
L +10 or more: 17%
+9 to −9: 59%
−10 or more: 24%
Subgroups:
▸ BCVA outcome not
significantly affected by
cataract surgery
CMT (OCT):
CMT (µm) p Value
IVTL −137.1 NS vs L
L −109.6
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Table 7 Continued
Study
Participants and baseline
values Intervention
Outcome (change from
baseline at study end)
Kim et al45
Korea
Design: 2-arm RCT
Follow-up: 3 years
N: 86 eyes of 75 patients
Inclusion criteria: diffuse DMO
Exclusion criteria: not reported
Age: not reported
Sex: not reported
Diabetes type: not reported
HbA1c: not reported
Baseline VA: not reported
Baseline CMT: not reported
Comorbidities: not reported
Group 1 (IVT, n=38 eyes):
4 mg IV triamcinolone (1.88
additional treatments,
completion 68.1%)
Group 2 (IVTL, n=48 eyes):
macular laser
photocoagulation 4 weeks
after 4 mg IV triamcinolone
(0.92 additional treatments,
completion 77.1%)
Regimen for all groups:
additional treatment possible,
criteria not mentioned
Laser protocol not reported
At 3 years
BCVA: not reported
Outcomes related to DMO:
No DMO
recurrence
p Value
IVT 3.9%
IVTL 24.3% 0.028 vs IVT
Time DMO not present
IVT 10.33 months
IVTL 19.88 months 0.027 vs IVT
Lam et al34
Hong Kong
Design: 3-arm RCT
Follow-up: 6 months
(2 years planned)
N: 111 eyes of 111 patients
Inclusion criteria: >18 years, type
1 or 2 DM, clinically significant
DMO (ETDRS), CMT ≥250 µm
Exclusion criteria: macular
oedema due to causes other
than diabetic maculopathy, signs
of vitreomacular traction,
proliferative diabetic retinopathy,
aphakia, history of glaucoma or
ocular hypertension, macular
ischemia, any laser procedure
within 3 months, ocular surgery
within 6 months, significant
media opacities
Age: 64.7–67.2 SD8.2–10.3
years
Sex: 42–59% female
Diabetes type: not reported
HbA1c: not reported
Baseline VA: ETDRS logMAR
0.64–0.72 SD0.34–0.36
Baseline CMT: 385–424
SD91–108 µm
Comorbidities: 66–84% phakic
eyes
Group 1 (IVT, n=38 eyes):
4 mg IV triamcinolone (no
retreatments)
Group 2 (IVTL, n=36 eyes):
4 mg IV triamcinolone
followed by grid laser
photocoagulation (ETDRS)
(laser treatment once the
macular oedema had reduced
to <250 µm at the foveal
center or at 1 to 2 months
after injection, whichever was
earlier)
Group 3 (L, n=37 eyes): grid
laser photocoagulation (n=3
retreatments) (no
retreatments)
Regimen for all groups: in
case of recurrence or
persistence of macular
oedema, retreatment offered
according to study group, at
intervals no less than
4 months
Laser ETDRS protocol
At 6 months
BCVA (ETDRS):
BCVA
improvement
p Value
IVT −0.7 SD 10.7 log
MAR
Plus ≥15 letters:
5%
NS between
groups
IVTL −1.1 SD 10.8 log
MAR
Plus ≥15 letters:
3%
L −1.6 SD 11.5 log
MAR
Plus ≥15 letters:
5%
CMT (OCT):
CMT (µm) p Value
IVT 342 SD124 (−54) NS between
groups, <0.01 vs
baseline
IVTL 307 SD181 (−116) <0.01 vs
baseline
L 350 SD169 (−35)
Continued
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Table 7 Continued
Study
Participants and baseline
values Intervention
Outcome (change from
baseline at study end)
Ockrim et al/Sivaprasad
et al42 62
UK
Design: 2-arm RCT
Follow-up: 1 year
N: 88 eyes of 88 patients
Inclusion criteria: clinically
significant DMO persisting
≥4 months, ≥1 previous laser
treatment, BCVA 6/12–3/60, VA
in fellow eye ≥3/60, duration
visual loss <24 months
Exclusion criteria: significant
macular ischemia, baseline IO
>23 mm Hg, glaucoma,
coexistent renal disease, loss of
VA due to other causes, previous
vitrectomy, intraocular surgery
within 3 months of study entry,
previous inclusion in other DR
trials, inability to return to
follow-up, inability to give
informed consent
Age: 62.3–64.8 SD7.5–10.1
years
Sex: 28.9–34.9% female
Diabetes type: 97.8–100% type
2 DM
HbA1c: 7–7.8 IQR6.5–8.7%
Baseline VA: ETDRS letter score
53.0–54.6 SD13.3–14.2
Baseline CMT: 410.4–413.4
SD127.8–134.1 µm
Comorbidities: 17.8–19.5% PDR,
13.3–18.6% pseudophakia,
15–17.8% posterior vitreous
detachment
Group 1 (IVT, n=43 eyes):
4 mg IV triamcinolone (mean
number of IVT injections 1.8
(range 1–3))
Group 2 (L, n=45 eyes):
ETDRS laser
photocoagulation (mean
number of grid laser sessions
2.1 (range 1–3))
Regimen for all groups:
patients retreated at 4 and
8 months if they had
persistent macular oedema
Laser ETDRS protocol
At 12 months
BCVA (ETDRS):
BCVA (letters) p Value
IVT −0.2 NS vs L
L +1.7
Plus ≥15 letters
IVT 4.8% NS vs L
L 12.2%
CMT (optical coherence
tomography):
CMT (µm) p Value
IVT −91.3 NS vs L
L −63.7
BCVA, best corrected visual acuity; C, control; CMT, central macular thickness; CPL, control plus laser; CSME, clinically significant macular oedema; DDS, dexamethasone; DIL,
dexamethasone followed by laser; DM, diabetes mellitus; DMO, diabetic macular oedema; DP, diastolic pressure; DR, diabetic retinopathy; HR QoL, health-related quality of life; IOP, intraocular
pressure; IV, intravitreal; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib; IVR, intravitreal ranibizumab; IVT, intravitreal triamcinolone; IVTL, intravitreal triamcinolone plus laser; IVVTE,
intravitreal VEGF Trap Eye; L, laser; MLT/MPC, macular laser therapy/macular photocoagulation; NEI VFQ-25, National Eye Institute Visual Function Questionnaire-25; NPDR, non-proliferative
diabetic retinopathy; NR, not reported; OCT, optical coherence tomography; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation; RCT, randomised controlled trial; RDL,
ranibizumab plus deferred laser; RPL, ranibizumab plus laser; SOC, standard of care; SP, systolic pressure; SRFA, fluocinolone; TPL, triamcinoloine plus laser; VA, visual acuity; VEGF,
vascular endothelia growth factor.
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Table 8 Trials assessing more than one drug
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
Ahmadieh et al31
Iran
Design: 3-arm
placebo-controlled RCT
Follow-up: 24 weeks
N: 115 eyes of 101 patients
Inclusion criteria: eyes with clinically
significant DMO unresponsive to previous
macular laser photocoagulation (last
session >3 months prior)
Exclusion criteria: visual acuity ≥20/40;
history of cataract surgery within past
6 months; prior intraocular injection or
vitrectomy, glaucoma or ocular
hypertension; PDR with high-risk
characteristics; vitreous hemorrhage;
significant media opacity; presence of
traction on the macula; pregnancy; serum
creatinine ≥3 mg/100 ml; monocular
patients
Age: 59.7 SD8.3 years (range 39–74)
Sex: 50.5% female
Diabetes type: not reported, 27.6–33.3%
on insulin
HbA1c: 9.35–10.06%
Baeline VA: not reported
Baseline CMT: not reported
Comorbidities: (percentage of eyes)
13.9% history of cataract surgery, 81.7%
NPDR, 4.3% early PDR, 13.9% regressed
PDR; no iris neovascularisation
Group 1 (IVB, n=41 eyes):
bevacizumab 1.25 mg
(0.05 ml)
Group 2 (IVB/IVT, n=37
eyes): combined
bevacizumab (1.25 mg
(0.05 ml)) and
triamcinolone (2 mg
(0.05 ml)), followed by two
injections of bevacizumab
alone
Group 3 (C, n=37 eyes):
sham injection
Regimen for all groups: 3
consecutive IV injections at
6-week intervals
At 24 weeks
BCVA (Snellen chart):
BCVA (logMAR),
95% CI
p Value
IVB −0.18 (–0.29,
−0.08) (+9 letters
(4, 14.5))
0.01 vs C, NS vs
IVB/IVT
IVB/IVT −0.21 (−0.30,
−0.12) (+10.5
letters (6, 15))
0.006 vs C
C −0.03 (−0.08, 0.14)
(+1.5 letters
(−7, 4))
CMT (OCT):
CMT (µm), 95% CI p Value
IVB −95.7
(−172.2, −19.3)
0.012 vs C, NS vs
IVB/IVT
IVB/IVT −92.1
(−154.4, −29.7)
0.022 vs C
C 34.9 (7.9, 61.9)
ATEMD Oliveira Neto
et al56
Multicenter
Design: 3-arm RCT
Follow-up: 6 months
Note: only 48.3%
completion
N: 120 eyes of 120 patients
Inclusion criteria: DMO, BCVA 20/40–20/
400, CMT ≥275 µm
Exclusion criteria: PDR, laser
photocoagulation in previous 3 months, no
IV corticosteroid or anti-VEGF in previous
3 months
Age: not reported
Sex: not reported
Diabetes type: not reported
HbA1c: not reported
Baseline VA: not reported
Baseline CMT: not reported
Comorbidities: not reported
Group 1 (IVB, n=NR eyes):
1.25 mg (0.05 ml) of IV
bevacizumab
Group 2 (IVT, n=NR eyes):
4 mg (0.1 ml) of IV
triamcinolone acetonide
Group 3 (IVB/IVT, n=NR
eyes): 1.25 mg (0.05 ml) of
IV bevacizumab plus 4 mg
(0.1 ml) of IV triamcinolone
acetonide
Regimen for all groups:
monthly injections
At 6 months
BCVA:
▸ no significant difference between
groups (between 1.7 and 2.3 lines
gained in the different groups in
2010 report (n=18))
CMT (OCT):
▸ CMT reduced in all 3 groups
(between 17 and 33% reduction in the
different groups in 2010 report (n=18));
no significant difference between groups
Continued
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Table 8 Continued
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
DRCR Network 2010
(Elman et al)21 46
USA
Multicenter
Design: 4-arm
placebo-controlled RCT
Follow-up: 1–2 years;
2 years extension
(Elman)46 for
consenting patients
N: 854 eyes of 691 patients
Inclusion criteria: ≥18 years, type 1 or 2
DM; study eye: (1) BCVA letter score
78–24 (20/32–20/320), (2) definite retinal
thickening due to DMO assessed to be
main cause of visual loss, (3) retinal
thickness measured on time domain OCT
≥250 µm in central subfield (2 study eyes
per patient could be included if both were
eligible at study entry)
Exclusion criteria: (1) treatment for DMO
within the prior 3 months, (2) panretinal
photocoagulation within the prior 4 months
or anticipated need for panretinal
photocoagulation within the next
6 months, (3) major ocular surgery within
the prior 4 months, (4) history of
open-angle glaucoma or steroid-induced
IOP elevation, requiring IOP-lowering
treatment, (5) IOP ≥25 mm Hg; systolic
pressure >180 mm Hg, diastolic pressure
>110 mm Hg; myocardial infarction, other
cardiac event requiring hospitalisation,
cerebrovascular accident, transient
ischemic attack, treatment for acute
congestive heart failure within 4 months
before randomisation
Age: median 62–64 years (25th, 75th
centile 55–58, 69–70)
Sex: 41–46% female
Diabetes type: 6–9% type 1 DM, 89–92%
type 2 DM, 2–3% uncertain
HbA1c: median 7.3–7.5% (25th, 75th
centile 6.5–6.7, 8.3–8.6)
Baseline VA: letter score 63 SD12
(∼20/63 SD2.4 lines)
Baseline CMT: 405 SD134 µm
Comorbidities: 60–67% prior treatment for
Group 1 (CPL, n=293
eyes): sham injection plus
prompt (within 3–10 days
after injection) focal/grid
photocoagulation
Group 2 (RPL, n=187
eyes): 0.5 mg IV
ranibizumab plus prompt
focal/grid photocoagulation
Group 3 (RDL, n=188
eyes): 0.5 mg IV
ranibizumab plus deferred
(≥24 weeks) focal/grid
photocoagulation
Group 4 (TPL, n=186
eyes): 4 mg IV
triamcinolone plus prompt
focal/grid photocoagulation
Regimen for all groups:
Baseline treatment 0.5 mg
IV ranibizumab and 4 mg
preservative free
triamcinolone; study
treatment every 4 weeks
up to 12 weeks, then
retreatment algorithm: 16
to 20 weeks, monthly
retreatment unless
‘success’ criteria were met
(visual acuity letter score
≥84 (20/20) or OCT
central subfield thickness
<250 µm); 24–48 weeks,
patients subdivided
(according to predefined
criteria) into ‘success’,
‘improvement’, ‘no
improvement’ or ‘failure’;
At 1 year
BCVA (E-ETDRS Visual
Acuity Test): BCVA (letters) p Value
CPL +3 SD13
RPL +9 SD11 <0.001 vs CPL
RDL +9 SD12 <0.001 vs CPL
TPL +4 SD13 NS vs CPL
BCVA gain categories (letters)
CPL +10 or more: 28%
+9 to −9: 59%
−10 or more: 13%
RPL +10 or more: 50%
+9 to −9: 45%
−10 or more: 4%
<0.001 vs CPL
RDL +10 or more: 47%
+9 to −9: 51%
−10 or more: 3%
<0.001 vs CPL
TPL +10 or more: 33%
+9 to −9: 52%
−10 or more: 14%
NS vs CPL
Subgroups:
▸ BCVA results in TPL group
substantially better for
pseudophakic eyes than for
phakic eyes (comparable to
results for RPL and RDL
groups) (p not reported)
▸ No difference in results
according to prior treatment
for DMO, baseline VA,
baseline CMT, baseline
level of retinopathy, focal or
diffuse oedema
CMT (OCT):
CMT (µm) p Value
CPL −102 SD151
RPL −131 SD129 <0.001 vs CPL
RDL −137 SD136 <0.001 vs CPL
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Table 8 Continued
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
DMO; 61–68% with NPDR, 26–36% with
PDR or PDR scars
‘improvement’ group
continued treatment, other
groups treated at
investigator discretion;
alternative treatment
permitted if eye met criteria
for ‘failure’ or ‘futility’. In
the case of retreatment,
ranibizumab could be
given as often as every
4 weeks, and
triamcinolone every
16 weeks (with sham
injections as often as
every 4 weeks).
Retreatment for focal/grid
laser (after ≥13 weeks
from previous treatment) if
there was oedema
involving or threatening the
center of the macula and if
complete laser had not
been given; retreatment
algorithms facilitated by
web-based real-time data
entry system. Median
number of drug injections
before 1 year visit was 8–9
for ranibizumab, 3 for
triamcinolone, and 5 sham
injections. Retreatment
between 1 and 2 years
(Elman 2011): median
injections 2 in RPL group,
3 in RDL group; in TPL
group 68% of eyes
received at least 1
injection; at least one focal/
grid laser sessions
between 1 and 2 years:
51% CPL, 40% RPL, 29%
RDL, 52% TPL
TPL −127 SD140 <0.001 vs CPL
Subgroups:
▸ pattern of CMT decrease
similar for groups with CMT
<400 and ≥400 µm at
baseline
▸ Significantly more patients
with severe NPDR or worse
improved by 2 levels or
more in the ranibizumab
groups (28%, no significant
change in the other groups)
At 2 years (expanded results,
Elman 2011)
BCVA (E-ETDRS Visual
Acuity Test):
BCVA (letters) p Value
CPL (n=211) +3 SD15
RPL (n=136) +7 SD13 0.03 vs CPL
RDL (n=139) +9 SD14 <0.001 vs CPL
TPL (n=142) +2 SD19 NS vs CPL
BCVA gain categories (letters)
CPL +10 or more: 36%
+9 to −9: 52%
−10 or more: 13%
RPL +10 or more: 44%
+9 to −9: 49%
−10 or more: 7%
NS vs CPL
RDL +10 or more: 49%
+9 to −9: 48%
−10 or more: 3%
0.01 vs CPL
TPL +10 or more: 41%
+9 to −9: 40%
−10 or more: 19%
NS vs CPL
CMT (OCT):
CMT (µm) p Value
CPL −138 SD149
RPL −141 SD155 0.003 vs CPL
RDL −150 SD143 0.01 vs CPL
TPL −107 SD145 NS vs CPL
Continued
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Table 8 Continued
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
Laser Modified ETDRS
protocol as used in prior
DRCR.net protocols
Jorge et al51
Brazil
Design: Prospective
RCT
Follow-up: 24 and
48 weeks (to date, 73%
and 56% of patients
completed 24 and
48 weeks, respectively)
N: 63 eyes of 47 patients
Inclusion criteria: Refractory
cener-involving DMO
Exclusion criteria: NR
Age: NR
Sex: NR
Diabetes type: NR
HbA1c: NR
Baseline VA: NR
Baseline CMT: NR
Comorbidities: NR
Group 1 (IVB 1.5 mg,
n=NR): injections at
baseline and monthly if
CSFT (central subfield
thickness) measured by
SDOCT (spectral domain
OCT) >275 µm
Group 2 (IVR 0.5 mg,
n=NR): injections at
baseline and monthly if
CSFT >275 µm
At 48 weeks
BCVA
Mean BCVA
reduction from
baseline (logMAR)
p Value
IVB1.5 −0.21 vs baseline <0.05
at all-time points
vs IVR0.5: no
significant
difference at all
time-points
IVR0.5 −0.21 vs baseline <0.05
at all time-points
vs IVB1.5: no
significant
difference at all
time-points
CSFT
Mean CSFT
reduction from
baseline
p Value
IVB1.5 −129.6 µm vs baseline <0.05
at all-time points
vs IVR0.5 no
significant different
at all-time points
IVR0.5 −137.9 µm vs baseline <0.05
at all-time points
vs IVB1.5 no
significant different
at all-time points
At 12 months
Continued
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Table 8 Continued
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
Lim et al55
Korea
Design: 3-arm RCT
Follow-up: 12 months
N: 111 eyes of 105 patients
Inclusion criteria: eyes with clinically
significant
DMO based on ETDRS and DMO with
central macular thickness of at least
300 µm by optical coherence tomography
(OCT)
Exclusion criteria: unstable medical
status, including glycemic control and
blood pressure; any previous treatment for
DMO, including intravitreal, sub-Tenon
injection or macular photocoagulation,
history of vitreoretinal surgery,
uncontrolled glaucoma; proliferative
diabetic retinopathy with active
neovascularisation, previous panretinal
photocoagulation, presence of
vitreomacular traction, history of systemic
corticosteroids within 6 months,
contraindications for bevacizumab or
triamcinolone acetonide
Age: 60.4 SD 7.4 (range 48–70) years
Sex: 52% female
Diabetes type: NR
HbA1c: 7.2 SD 1.2–7.4 SD1.2
Baseline VA: 0.62 SD 0.23–0.65 SD 0.28
logMAR
Baseline CMT: 447 SD 110–458 SD
92 µm
Comorbidities: NR
Group 1 (IVB/IVT, n=36):
IV injection of 1.25 mg
(0.05 ml) IVB at 0 and
6 weeks and IV injection of
2 mg (0.05 ml) IVT at
0 weeks. Mean number of
addition injection 1.28
Group 2 (IVB, n=38): IV
injection of 1.25 mg
(0.05 ml) IVB at 0 and
6 weeks. Mean number of
injections 2.54.
Group 3 (IVT, n=37): IV
injection of 2 mg (0.05 ml)
IVT at 0 weeks. Mean
number of injections 1.04
Unclear if rescue laser was
available
IVB injections were
repeated if CMT appeared
>300 µm on OCT in at
least 6 weeks in all three
groups
BCVA (logMAR) p Value
IVB/IVT −0.15 0.088 (between
groups)IVB −0.16
IVT −0.16
CMT (µm) p Value
IVB/IVT −199 0.132 (between
groups)IVB −17s9
IVT −200
Continued
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Table 8 Continued
Study Participants and baseline values Intervention
Outcome (change from
baseline at study end)
Soheilian
et al37 41 54 141
Iran
Design: 3-arm RCT
Follow-up: 36 weeks
(Soheilian 2007 reports
12 week results of the
same trial, these were
not considered here)
N: 150 eyes of 129 patients
Inclusion criteria: eyes with clinically
significant DMO (ETDRS criteria)
Exclusion criteria: previous panretinal of
focal laser photocoagulation, prior ocular
surgery or injection, history of glaucoma
or ocular hypertension, VA ≥20/40 or <20/
300, iris neovascularisation, high risk
PDR, significant media opacity,
monocularity, pregnancy, serum creatinine
≥3 mg/dL, uncontrolled DM
Age: 61.2 SD6.1 years
Sex: 47.3% female
Diabetes type: not reported
HbA1c: not reported
Baseline VA: 0.55–0.73 SD0.26–0.28
logMAR
Baseline CMT: 300–359 SD118–149 µm
Comorbidities: 94% NPDR, 6% early PDR
Group 1 (IVB, n=50 eyes):
IV injection of
bevacizumab 1.25 mg
(0.05 ml) (retreatment IVB
14 eyes)
Group 2 (IVB/IVT, n=50
eyes): IV injection of
combined bevacizumab
(1.25 mg (0.05 ml)) and
triamcinolone (2 mg
(0.05 ml)), followed by two
injections of bevacizumab
alone (retreatment IVB/IVT
10 eyes)
Group 3 (MPC, n=50
eyes): focal or modified
grid laser (retreatment
MPC 3 eyes)
Regimen for all groups:
Retreatments performed at
12 week intervals as
required
At 36 weeks
BCVA (Snellen chart):
BCVA (logMAR),
SD
p Value
IVB −0.28 SD0.25 (+14
SD12.5 letters)
0.053 vs IVB/IVT or
MPC
IVB/IVT −0.04 SD0.33 (+2
SD16.5 letters)
NS vs MPC
MPC
+0.01 SD0.27
(−0.5 SD13.5
letters)
Snellen line
changes
IVB +2 lines or more:
37%
stable within 2
lines: 59.3%
−2 lines or more:
3.7%
NS between
groups
IVB/IVT +2 lines or more:
25%
stable within 2
lines: 54.2%
−2 lines or more:
20.8%
MPC +2 lines or more:
14.8%
stable within 2
lines: 66.7%
−2 lines or more:
18.5%
CMT (OCT):
CMT (µm), SD p Value
IVB −56 SD140 0.044 vs baseline,
NS between
groups
IVB/IVT −5 SD113
MPC −8 SD67
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Adverse events are shown in tables 9 and 16.
Conjunctival haemorrhages were higher in the ranibizu-
mab arms compared with laser (RESTORE) or no treat-
ment (RESOLVE). In the RESOLVE, RISE and RIDE
studies, a considerably higher incidence of intraocular
pressure (IOP) increase was reported in the ranibizu-
mab arm compared to control. This increase in IOP was
not demonstrated in the RESTORE study. There were
no consistent differences in systemic adverse events
between ranibizumab and laser or placebo.
Bevacizumab
Eight RCTs investigating the use of bevacizumab in
DMO were identiﬁed (tables 4 and 8). One RCT, the
BOLT study (n=80), randomised patients to laser
therapy or 1.25 mg intravitreal bevacizumab.23 52 At
24 months, the mean changes in BCVA and the propor-
tion of patients who gained 10 ETDRS letters or more
was statistically signiﬁcantly higher in the bevacizumab
arm than in the laser arm. Faghihi et al53 (n=80) com-
pared 1.25 mg bevacizumab (average 2.23 injections per
patient) with 1.25 mg bevacizumab plus a single laser
treatment (average 2.49 injections per patient). After
6 months, the authors found both treatments to be
effective at improving BCVA, but neither treatment was
found to result in a greater beneﬁt.
Lam et al35 (n=52) compared two doses of bevacizu-
mab (1.25 and 2.5 mg) in patients with diffuse DMO.
Patients with focal DMO associated with localised retinal
thickening were excluded. At 6 months, following 3
initial monthly injections (no treatment in the remain-
ing 3 months), both groups showed a statistically signiﬁ-
cantly increased mean BCVA compared with baseline
vision, but there was no difference between doses.
Four trials have investigated the combination of beva-
cizumab and triamcinolone. Ahmadieh et al31 (n=115)
compared combined bevacizumab (three 1.25 mg injec-
tions at 6 week intervals) plus triamcinolone (2 mg base-
line injection only, Triamhexal) with bevacizumab alone
(three 1.25 mg at 6 week intervals) and sham injection
in patients who had DMO unresponsive (deﬁnition not
reported) to previous laser (last session more than
3 months previously). The combination arm and bevaci-
zumab alone arm improved mean BCVA more than the
sham injection. For BCVA, the combination of bevacizu-
mab plus triamcinolone was non-statistically signiﬁcantly
better than bevacizumab alone.
Soheilian et al37 41 (n=150) compared combined beva-
cizumab (1.25 mg) plus triamcinolone (2 mg) with beva-
cizumab alone and laser alone in patients who were
laser naïve. At 36 weeks, bevacizumab alone improved
BCVA more than either combination therapy or laser,
although the difference was not statistically signiﬁcant.
Extended follow-up at 24 months showed that there was
no statistically signiﬁcant difference between groups for
BCVA; however, the direction of effect favours the bevaci-
zumab and combination arms more than the laser.54
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Table 9 Ranibizumab safety data
READ-2 study28 47 RESOLVE study36 RESTORE study24 RISE study38 RIDE study38
Number of patients IVR: n=42; L: n=42;
IVRL: n=42
IVR0.3: n=51; IVR0.5:
n=51; C: n=49
IVR: n=116; IVRL:
n=118; L: n=111
IVR0.3: 125; IVR0.5: 126;
C: 123
IVR0.3: 125; IVR0.5: 124; C: 127
Ocular adverse events
Eye pain NR IVR0.3: n=9 (18%);
IVR0.5: n=9 (18%); C:
n=10 (20%)
IVR: n=13 (11%);
IVRL: n=10 (8%); L:
n=12 (11%)
IVR0.3: 26%; IVR0.5: 21%;
C: 19%
IVR0.3: 8%; IVR0.5: 12.9%; C: 7.1%
Conjunctival
hyperaemia
NR NR IVR: n=9 (8%); IVRL:
n=6 (5%); L: n=6 (5%)
NR NR
Conjunctival
haemorrhage
NR IVR0.3: n=10 (20%);
IVR0.5: n=13 (25%); C:
n=7 (14%)
IVR: n=8 (7%); IVRL:
n=10 (8%); L: n=0
IVR0.3: 54%; IVR0.5: 52%;
C: 32%
IVR0.3: 40.8%; IVR0.5: 50%; C: 31.5%
IOP increase NR IVR0.3: n=6 (12%);
IVR0.5: n=15 (29%); C:
n=1 (2%)
IVR: n=1 (<1%);
IVRL: n=1 (<1%);
IVR0.3: 20%; IVR0.5: 14%;
C: 2%
IVR0.3 : 15.2%;IVR0.5: 18.5%; C: 11%
Vitreous
haemorrhage
IVR: n=1 (2%); L: n=4
(10%); IVRL: n=3 (7%)
IVR0.3: n=1 (2%);
IVR0.5: n=0; C: n=0
NR IVR0.3: 3.2%; IVR0.5:
3.2%; C: 13%
IVR0.3: 0.8%; IVR0.5: 2.4%; C: 15%
Substantial
worsening of DMO
L: n=1 (2%) NR NR NR
Retinal ischaemia NR IVR0.3: n=0; IVR0.5:
n=1 (2%); C: n=0
NR NR NR
Retinal artery
occlusion
NR IVR0.3: n=0; IVR0.5:
n=1 (2%); C: n=0
NR NR NR
Endophthalmitis NR IVR0.3: n=1 (2%);
IVR0.5: n=1 (2%); C:
n=0
NR IVR0.3: 0.8%; IVR0.5: 0;
C: 0
IVR0.3+IVR0.5: 1.2%; C: 0%
Retinal detachment NR IVR0.3: n=0; IVR0.5:
n=0; C: n=1 (2%)
NR IVR0.3: 0.8%; IVR0.5: 0;
C: 0.8%
IVR0.3+IVR0.5: 0.4%; C: 0%
Neovascularisation NR NR NR IVR0.3: 0; IVR0.5: 0;
C: 0.8%
IVR0.3: 0.8%; IVR0.5: 0.8%; C: 5.5%
Traumatic cataract NR NR NR IVR0.3: 0.8%; IVR0.5:
0.8%; C: 0
IVR0.3+IVR0.5: 0.4%; C: 0%
Uveitis NR NR NR NR IVR0.3+IVR0.5: 0.4%; C: 0%
Macular oedema NR NR NR IVR0.3: 16.8%; IVR0.5:
20.6%; C: 21.1%
IVR0.3: 19.2%; IVR0.5: 13.7%; C:
20.5%
Retinal exudates NR NR NR IVR0.3: 19.2%; IVR0.5:
17.5%; C: 20.3%
IVR0.3: 16%; IVR0.5: 15.3%; C: 11%
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Table 9 Continued
READ-2 study28 47 RESOLVE study36 RESTORE study24 RISE study38 RIDE study38
Retinal
haemorrhage
NR NR NR IVR0.3: 12.8%; IVR0.5:
12.7%; C: 20.3%
IVR0.3: 15.2%; IVR0.5: 22.6%;
C: 18.9%
Cataract NR NR NR IVR0.3: 16.8%; IVR0.5:
11.9%; C: 14.6%
IVR0.3: 20%; IVR0.5: 23.4%; C: 23.6%
Vitreous detachment NR NR NR IVR0.3: 13.6%; IVR0.5:
11.1%; C: 15.4%
IVR0.3: 8.8%; IVR0.5: 12.9%; C: 15%
Ocular hyperemia NR NR NR IVR0.3: 15.2%; IVR0.5:
11.1%; C: 10.6%
IVR0.3: 3.2%; IVR0.5: 3.2%; C: 7.9%
Vitreous floaters NR NR NR IVR0.3: 12.8%; IVR0.5:
14.3%; C: 5.7%
IVR0.3: 7.2%; IVR0.5: 8.1%; C: 3.1%
Eye irritation NR NR NR IVR0.3: 10.4%; IVR0.5:
9.5%; C: 6.5%
IVR0.3: 5.6%; IVR0.5: 5.6%; C: 3.1%
Foreign body
sensation in eyes
NR NR NR IVR0.3: 12.8%; IVR0.5:
7.1%; C: 4.1%
IVR0.3: 8%; IVR0.5: 2.4%; C: 5.5%
Systematic adverse events
Arterial
thromboembolic
events
Stroke in 1 pt (2%) in
IVRL group- not related
to study drug
IVR0.3: n=0; IVR0.5:
n=3 (6%); C: n=2 (4%)
IVR: n=6 (5%); IVRL:
n=1 (<1%); L: n=1
(<1%)
IVR0.3: 3.2% (n=1 stroke);
IVR0.5: 7.9% (n=5 strokes);
C: 7.3% (n=2 strokes)
IVR0.3: 1.6% (stroke), 5.6% (heart
attack); IVR0.5: 2.4% (stroke), 2.4%
(heart attack); C: 1.6% (stroke), 5.6%
(heart attack)
Hypertension NR IVR0.3: n=4 (8%);
IVR0.5: n=5 ((10%); C:
n=5 (10%)
IVR: n=9 (8%); IVRL:
n=6 (5%); L: n=9 (8%)
Serious
IVR0.3: 0.8%; IVR0.5:
3.2%; C: 0.8%
Serious
IVR0.3: 1.6%; IVR0.5: 1.6%; C: 0%
Non-ocular
haemorrhage
NR IVR0.3: n=1 (2%);
IVR0.5: n=1 (2%); C:
n=0
IVR: n=1 (<1%);
IVRL: n=0; L: n=1
(<1%)
NR NR
Proteinuria NR NR IVR: n=1 (<1%);
IVRL: n=1 (<1%); L:
n=0
NR NR
Deaths 1 (2%) due to CVA in
IVRL group
NR IVR: n=2 (2%); IVRL:
n=2 (2%); L: n=2 (2%)
IVR0.3: 2.4%; IVR0.5: 4%;
C: 0.8%
IVR0.3: 3.2%; IVR0.5: 4.8%; C: 1.6%
C, control; DMO, diabetic macular oedema; IOP, intraocular pressure; IVR, intravitreal ranibizumab; IVRL, intravitreal ranibizumab plus laser; L, laser; NR, not reported.
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Table 10 Bevacizumab safety
BOLT study23 52 Lam et al35 Faghihi et al53
Number of patients MLT: n=38; IVB: n=42 IVB1.25, n=26; IVB2.5, n=26 IVB1.25 n=40 IVB 1.25
plus MLT n=40
Ocular adverse events Not reported
Loss of _15 or _30 ETDRS letters MLT: n=1 transient, 3 at 24 month analysis;
IVB: n=4 transient
No significant ocular events (IOP increase, retinal
tear, retinal detachment, endophthalmitis); no
significant difference in change in cataract scores
between groups
Vitreous haemorrhage MLT: n=1; IVB: n=0
Eye pain/irritation/watering during or
after injection
MLT:n=0; IVB: n=8
Red eye after injection MLT: n=0; IVB: n=8
Endophthalmitis NR
Transient IOP increase ≥30 mm Hg—MLT: 0; IVB:
n=4≥45 mm Hg—MLT: n=1; IVB: n=1
Floaters after injection MLT: n=0; IVB: n=2
Corneal epithelial defect MLT:n=0; IVB:n=1
Vitreomacular traction with macular
oedema
MLT: n=1; IVB: n=0
Systematic adverse events
Anaemia MLT: n=1; IVB: n=0 No systematic adverse effects (1 patient in 1.25 mg
group with foot gangrene requiring amputation due to
worsening diabetic neuropathy, considered unrelated
to treatment)
Vomiting after FFA MLT: n=1; IVB: n=0
Uncontrolled hypertension MLT:n=0; IVB: n=1
Polymyalgia rheumatica MLT:n=0; IVB: n=1
Intermittent claudication MLT:n=0; IVB: n=1
Gastroenteritis MLT:n=0; IVB: n=1
Fall MLT:n=2; IVB: n=0
Urinary tract infection MLT:n=0; IVB: n=1
Chest infection MLT:n=0; IVB: n=1
Headaches, dizziness, tiredness MLT:n=1; IVB: n=0
Bell palsy MLT:n=1; IVB: n=0
Admission for diabetic foot ulcer MLT:n=1; IVB: n=1
Admission for cholecystectomy MLT:n=0; IVB: n=1
Admission for fall/loss of
consciousness
MLT:n=1; IVB: n=0
Angina—hospital admission MLT:n=1; IVB: n=0
Cerebrovascular accident MLT:n=1; IVB: n=0
Myocardial infarction MLT:n=0; IVB: n=2
Coronary artery bypass graft MLT:n=0; IVB: n=1
Dyspnea, chest pain–admitted for
hospital observation
MLT:n=0; IVB: n=1
Death NR
ETDRS, Early Treatment Diabetic Retinopathy Study; FFA, fundus fluorescein; IOP, intraocular pressure; IVB, intravitreal bevacizumab; MLT, macular laser therapy; NR, not reported.
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Lim et al55 (n=111) also evaluated the combination of
bevacizumab plus triamcinolone when compared with
bevacizumab alone or triamacinolone alone. At
12 months, the authors found no statistically signiﬁcant
difference between groups for BCVA or CMT.
The Efﬁcacy Study of Triamcinolone and Bevacizumab
Intravitreal for Treatment of Diabetic Macular Oedema
(ATEMD) study, currently only published in abstract
form, compared combined therapy with bevacizumab
(1.25 mg) and triamcinolone (4 mg) with each of these
alone.56 At 6 months, they found no statistically signiﬁ-
cant difference between groups. One study comparing
bevacizumab with ranibizumab is discussed above.51 No
bevacizumab trials were suitable for meta-analysis
because treatment arms were not comparable among
included studies.
Adverse events are shown in tables 10 and 16.There
was a low frequency of adverse events reported in the
included trials. A higher incidence of mild anterior
chamber reaction was reported in bevacizumab groups
compared with controls. The incidence of IOP increase
was comparable between bevacizumab and laser.
Soheilian et al37 41 were the only authors to report the
incidence of lens opacity. No patients in the bevacizu-
mab alone group were found to have lens opacities but
in four patients (8%) in the bevacizumab plus triamci-
nolone group, this ﬁnding was observed over the
36-week follow-up period.
Pegaptanib
Two studies have evaluated pegaptanib in DMO and
both compared it with sham injection (table 5).
Cunningham et al39 57 compare three doses of pegapta-
nib (0.3, 1 and 3 mg) and sham injection in laser-naive
patients (n=172). At 6 months, patients in the 0.3 and
1 mg groups performed statistically signiﬁcantly better
than those in either the 3 mg or sham groups. Six injec-
tions (median) were administered in the 0.3 and 1 mg
groups, whereas only ﬁve (median) injections were
administered in the 3 mg group.
The second trial (n=260), reported by Sultan and collea-
gues in 2011, compared pegaptanib (0.3 mg) and sham
injection. At 2 years, the pegaptanib group showed a statis-
tically signiﬁcantly greater improvement in mean BCVA
compared with sham.40 However, there was no statistically
signiﬁcant difference in the proportion of patients with an
improvement of 10 letters or more. Patients were allowed
rescue laser at the assessors’ discretion (25.2% of patients
in the pegaptanib group and 45% of patients in the sham
group received rescue treatment). In regard to
meta-analysis, data were only available to combine these
trials for the proportion of patients with more than 15
letter gain. Although neither trial individually demon-
strated a statistically signiﬁcant difference favouring pegap-
tanib over sham (ﬁgure 5), when pooled together in
meta-analysis, a statistically signiﬁcant difference was found
in favour of pegaptanib (OR 1.94, 95% CI 1.01 to 3.71).
Table 11 Pegaptanib safety
Cunningham et al / Adamis et al39 57 Sultan et al40
Number of patients IVP0.3, n=44 eyes; IVP1, n=44 eyes; IVP3, n=42 eyes IVP, n=133 eyes; C, n=127 eyes
Ocular adverse events
Eye pain Pegaptanib: 31%; C: 17% IVP: 11.1%; C: 7%
Vitreous haemorrhage Pegaptanib: 22%; C: 7% IVP: 6.3%; C: 7.7%
Punctuate keratitis Pegaptanib: 18%; C: 17% IVP: 11.8%; C: 6.3%
Cataract Pegaptanib: 13%; C: 10% IVP: 8.3%; C: 9.2%
Eye discharge Pegaptanib: 11%; C: 10% NR
Conjunctival haemorrhage Pegaptanib: 10%; C: 0% IVP: 22.2%; C: 14.1%
Vitreous opacities Pegaptanib: 9%; C: 5% NR
Blurred vision Pegaptanib: 7%; C: 5% NR
Other vitreous disorder Pegaptanib: 7%; C: 0% NR
Other visual disturbance Pegaptanib: 7%; C: 0% NR
Culture-negative endophthalmitis Pegaptanib: n=1 NR
IOP increase NR IVP: 17.4%; C: 6.3%
Retinal haemorrhage NR IVP: 6.3%; C: 10.6%
Retinal exudates NR IVP: 6.3%; C: 5.6%
Conjunctivitis NR IVP: 5.6%; C: 4.2%
Lacrimation increased NR IVP: 5.6%; C: 2.8%
Diabetic retinal oedema NR IVP: 11.1%; C: 17.6%
Macular oedema NR IVP: 9.7%; C: 11.6%
Systemic adverse events
Non-ocular hypertension NR IVP: 13.9%; C: 9.9%
Cardiac disorders NR IVP: 6.9%; C: 5.6%
Deaths NR IVP: n=4
IOP, intraocular pressure; IVP, intravitreal pegaptanib; NR, not reported.
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Adverse events for pegaptanib are shown in table 11.
There was a higher incidence of eye pain compared to
control (31% vs 17%).39 57 Cataract formation was
similar between the pegaptanib and control groups.
There was a higher incidence of IOP increase in the
pegaptanib arm compared to control (17.4% vs 6.3%).40
Other anti-VEGF
Aﬂibercept has been evaluated in the Da Vinci study
(n=219)30 58 (table 5). Four regimens of aﬂibercept
(0.5 mg 4 weekly, 2 mg 4 weekly, 2 mg monthly for
3 months, then every 8 weeks, and 2 mg monthly for
3 months followed by treatment as required) were com-
pared with laser. At 6 months, all aﬂibercept arms had a
statistically better BCVA and CMT change than the laser
arm. The regimen that resulted in the greatest BCVA
gain and CMT reduction was 2 mg every 4 weeks;
however, statistical signiﬁcance between aﬂibercept arms
was not reported. One year extended follow-up showed
that all aﬂibercept arms were found to have a statistically
signiﬁcantly better BCVA compared to laser.58
Adverse events are shown in table 12. There was a
higher incidence of IOP increase and eye pain in the
aﬂibercept group compared with laser. Other adverse
events were too infrequent to draw meaningful conclu-
sions. The incidence of cataracts was not reported.
Steroids
Dexamethasone
Two included trials assessed the use of dexamethasone
to treat DMO (table 6): Haller 2010 (full text avail-
able)59 and Callanan (available to date only in an
abstract form).44 Haller 2010 (n=171) compared two
doses of dexamethasone, administered as an intravitreal
implant (350 and 700 µm) through a 20-gauge trans-
scleral incision, with no treatment. At 90 days only, the
700 µm group showed a statistically signiﬁcantly higher
proportion of patients with 10 or more letter gain
Table 12 Aflibercept safety
DA VINCI 201030 58
Number of patients IVVTE (all doses) n=175, laser n=44
Ocular adverse events
Conjunctival hemorrhage At 6 months: Laser 18.2%, IVVTE 18.9%
At 12 months: Laser 18.2%, IVVTE 26.9%
IOP increase At 6 months: Laser 2.3%, IVVTE 9.7%
At 12 months: Laser 2.3%, IVVTE 9.7%
Eye pain At 6 months: Laser 4.5%, IVVTE 8.6%
At 12 months: Laser 4.5%, IVVTE 13.7%
Ocular hyperaemia At 6 months: Laser 4.5%, IVVTE 6.3%
At 12 months: Laser 4.5%, IVVTE 7.4%
Vitreous floaters At 6 months: Laser 4.5%, IVVTE 5.1%
At 12 months: Laser 4.5%, IVVTE 6.9%
Endophthalmitis At 6 months: Laser 0%, IVVTE 1.1%
At 12 months: Laser 0%, IVVTE 1.1%
Uveitis At 6 months: Laser 0%, IVVTE 0.6%
At 12 months: Laser 0%, IVVTE 0.6%
Diabetic retinal oedema At 6 months: Laser 2.3%, IVVTE 0%
At 12 months: Laser 2.3%, IVVTE 4.6%
Visual acuity reduced At 6 months: Laser 2.3%, IVVTE 0%
At 12 months: Laser 2.3%, IVVTE 0%
Vitreous hemorrhage At 6 months: Laser 2.3%, IVVTE 0%
At 12 months: Laser 6.8%, IVVTE 0%
Corneal abrasion At 6 months: Laser 0%, IVVTE 0.6%
At 12 months: Laser 0%, IVVTE 4.6%
Retinal tear At 6 months: Laser 0%, IVVTE 0.6%
At 12 months: NR
Systematic events
Hypertension At 6 months: Laser 6.8%, IVVTE 9.7%
At 12 months: Laser 0%, IVVTE 1.7%
Myocardial infarction At 6 months: Laser 0%, IVVTE 1.1%
At 12 months: Laser 0%, IVVTE 1.7%
Cerebrovascular event At 6 months: Laser 0%, IVVTE1.1%
At 12 months: Laser 2.3%, IVVTE 1.7%
Death At 6 months: Laser 0%, IVVTE 1.7%
At 12 months: Laser 2.3%, IVVTE 4%
IOP, intraocular pressure; IVVTE, intravitreal vascular endothelial growth factor Trap Eye.
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compared to no treatment (33% compared with 12%,
p=0.007). The 350 µm group showed a non-statistically
signiﬁcant improvement compared with laser alone
(21% compared with 12%). At 180 days, there was no
statistically signiﬁcant difference between either the
dexamethasone group or no treatment group. The treat-
ment effect appeared to peak at 3 months.
The second trial, by Callanan and colleagues (n=253),
compared dexamethasone (dose not reported) plus
laser with laser alone. Although a greater improvement
in mean BCVA was seen at 1–9 months in the dexa-
methasone plus laser group compared with laser alone,
there was no statistically signiﬁcant difference at
12 months. A mean of 1.6 implants were used over the
12 month period.
These trials were not suitable for meta-analysis since
one study is only available in abstract form.
Adverse events are shown in table 13. In the 350 and
700 µm groups compared with no treatment, there was
a higher incidence of anterior chamber cells (29.1/26.4%
compared with 1.8%), anterior chamber ﬂare
(27.3/20.8% compared with 8.8%), vitreous haemorrhage
(20/22.6% compared with 5.3%) and increased IOP
(14.5/9.4% compared with 0%). However, there was no
statistically signiﬁcant difference in cataract formation
between groups at 12 months.59 Callanan et al44 reported
an increase in IOP in the dexamethasone plus laser group
compared with laser alone (20% compared with 1.6%).
Fluocinolone
Two trials assessed ﬂuocinolone implant for DMO
(table 6). The FAME study (n=956) compared two doses
of ﬂuocinolone (0.2 and 0.5 µg/day) with sham injec-
tion in patients with at least one prior laser treatment.29
Approximately 25% of patients in each group had more
than one prior laser treatment. At 24 months, both
doses of ﬂuocinolone showed a statistically signiﬁcant
improvement in mean BCVA compared to sham. There
was a modest difference between ﬂuocinolone groups.
Rescue laser was given after the ﬁrst 6 weeks for persist-
ent oedema and was allowed every 3 months. A range of
35–37% of patients in the ﬂuocinolone group and 59%
in the sham injection group required rescue laser.
Extended follow-up at 36 months showed that both the
ﬂuocinolone arms continued to result in a statistically
signiﬁcant beneﬁt compared with sham.60
Pearson et al43 (n=196) compared ﬂuocinolone
(0.59 mg) with standard of care, either laser or no treat-
ment. At 3 years, there was no statistically signiﬁcant dif-
ference in the proportion of patients with 15 letter gain
or more (31% ﬂuocinolone compared with 20% stand-
ard of care) between groups and the proportion of
patients losing 15 letters or more in the ﬂuocinolone
group (17% compared with 14%). Increased incidence
of cataracts may have contributed to this difference.
These trials were not suitable for meta-analysis.
Adverse events are shown in table 14. Pearson and col-
leagues reported a higher incidence of cataracts at
3 years in the ﬂuocinolone group compared with stand-
ard of care (55.9% compared with 21.7%). In the
extended report of the FAME study, there was a consid-
erably higher incidence of cataract surgery in phakic
eyes in the 0.2 and 0.5 µg/day ﬂuocinolone groups
(80% and 87.2% compared with 27.3%) and increased
IOP at any point (37% and 46% compared with 12%).
Following the demonstration in the FAME trial that a
lower dose was about as good as higher ones, the higher
doses are unlikely to be used.
Table 13 Dexamethasone safety
Callanan et al44 Haller et al59
Number of patients
Ocular adverse events
IOP elevation DIL: 20% (p<0.001); 1%
≥10 mm HgL: 1.6% ; 0% ≥10 mm Hg
Cataract NR NR
Anterior chamber
cells
NR DDS350: 29.1%; DDS700: 26.4%; C: 1.8%
Anterior chamber
flare
NR DDS350: 27.3%; DDS700: 20.8%; C: 8.8%
Vitreous
haemorrhage
NR DDS350: 20%; DDS700: 22.6%; C: 5.3%
Eye pain NR DDS350: 18.2%; DDS700: 9.4%; C: 3.5%
Vitreous disorder NR DDS350: 20%; DDS700: 15.1%; C: 3.5%
Increased IOP NR DDS350: 14.5%; DDS700: 9.4%; C: 0%
Conjunctival
haemorrhage
NR DDS350: 14.5%; DDS700: 7.5%; C: 0%
Vitreous floaters NR DDS350: 7.3%; DDS700: 17%; C: 0%
No significant differences in: reduced VA, eye irritation,
abnormal sensation in eye, macular oedema, eye pruritus,
retinal hemorrhage, DR, nonocular events
Dil, dexamethasone followed by laser; DDS, dexamethasone; IOP, intraocular pressure; NR, not reported.
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Triamcinolone
Ten trials evaluating triamcinolone were identiﬁed
(tables 7 and 8). All trials evaluated intravitreal adminis-
tration of triamcinolone, but there were no trials evaluat-
ing posterior or anterior subtenon injections. Two trials
used Trivaris,21 61 two trials used Kenacort,32 33 one trial
used Kenalog,62 one trial used Trimahexal31 and four
trials did not report the type of triamcinolone
used.34 3745 56 Three doses were assessed in the included
studies (1, 4 and 8 mg) and triamcinolone has been
combined with laser or bevacizumab.
Ip and colleagues (n=840) were the only authors to
evaluate triamcinolone 1 mg (Trivaris).22 61 63 64 They
found a statistically signiﬁcant improvement in mean
BCVA at 2 years in the laser group compared with the
triamcinolone group and no signiﬁcant difference
between 1 compared with 4 mg.
Several trials compared 4 mg intravitreal triamcino-
lone. Ip and colleagues (n=840) found that laser
therapy resulted in a greater improvement in mean
BCVA at 2 years compared to 4 mg triamcinolone
(Trivaris).22 61 63 64 Lam et al34 (n=111) found no
Table 14 Fluocinolone safety
FAME study (Campochiaro et al)29 60 Pearson et al43
Number of patients
Ocular adverse events
IOP at 12 months NR NR
Progression of cataract NR NR
Cataract NR SRFA: 55.9%;
SOC: 21.7%
Transient vitreous floaters NR NR
Transient subconjunctival
haemorrhage
NR NR
Cataract surgery SRFA0.2: 41.1% (74.9% of those without cataract surgery at baseline,
80% at 36 months); SRFA0.5: 50.9% (84.5% of those without cataract
surgery at baseline, 87.2% at 36 months); C: 7% (23.1% of those
without cataract surgery at baseline, 27.3% at 36 months)
NR
Glaucoma SRFA0.2: 1.6%; SRFA0.5: 2.3%; C: 0.5% NR
Increased IOP SRFA0.2: 3.2%; SRFA0.5: 3.3%; C: 0% SRFA: 69.3%;
SOC: 11.6%
IOP >30 mm Hg at any point
during 36 months
SRFA0.2: 18.4%; SRFA0.5: 22.9%; C: 4.3% NR
Trabeculectomy SRFA0.2: 2.1%; SRFA0.5: 4.8%; C: 0% NR
Other glaucoma surgery SRFA0.2: 1.3%; SRFA0.5: 1.3%; C: 0.5% NR
Trabeculoplasty SRFA0.2: 0.8%; SRFA0.5: 2.3%; C: 0% NR
Vitreous haemorrhage NR SRFA: 40.2%;
SOC: 18.8%
Abnormal sensation in eye NR SRFA: 37%;
SOC: 11.6%
Macular oedema NR SRFA: 34.6%
Eye pain NR SRFA: 26.8%;
SOC: 15.9%
Eye irritation NR SRFA: 22%;
SOC: 10.1%
Increased lacrimation NR SRFA: 22%;
SOC: 8.7%
Photophobia NR SRFA: 21.3%;
SOC: 21.7%
Blurred vision NR SRFA: 21.3%;
SOC: 15.9%
Vitreous floaters NR SRFA: 21.3%;
SOC: 8.7%
Systemic adverse events
Serious cardiovascular events SRFA0.2: 12%; SRFA0.5: 13.2%; C: 10.3%
Pruritus NR SRFA: 38.6%;
SOC: 21.7%
Deaths NR NR
IOP, intraocular pressure; NR, not reported; SOC, standard of care; SRFA, fluocinolone.
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Table 15 Triamcinolone safety
DRCR Network 2008
(Ip et al/Beck et al/
Bressler et al) 22 61 63 64
Gillies et al/Sutter
et al32 136–138 Gillies et al33
Kim
et al45 Lam et al34
Ockrim et al/
Sivaprasad et al42 62
Number of patients
Ocular adverse events
At 2 years (or 3 years when
indicated)
At 2 years – Not
reported
– At 12 months
IOP ≥30 mm Hg IVT1: n=22; IVT4: n=53; L: n=3 NR NR NR IVT: IOP significantly
higher than in L group
(18.2 mm Hg, range
12–26 mm Hg); no cases
of glaucoma
IOP >22 mm Hg NR NR NR IVT: 37%
(p=0.002 vs L);
IVTL: 36%
(p=0.002 vs L); L:
5%
NR
IOP ≥10 mm Hg from
baseline
IVT1: n=41; IVT4: n=85; L:
n=12
NR NR NR NR
IOP ≥5 mm Hg NR IVT: 68% (p=0.007
vs C); C: 10%
NR NR NR
IOP lowering
medication used
IVT1: n=31; IVT4: n=76; L:
n=25
IVT: 44% (p=0.0002
vs C); C: 3%
IVTL: 64% (p<0.001); L:
24%
NR NR
Cataract surgery IVT1: 23% (of those phakic at
baseline, 46% by 3 years
(p<0.001 between all groups);
IVT4: 51% (of those phakic at
baseline, 83% by 3 years); L:
13% (of those phakic at
baseline, 31% by 3 years)
IVT: 56% (of phakic
eyes over 3 years,
p<0.001 vs C); C: 8%
(of phakic eyes over
3 years)
NR NR
Ptosis NR NR NR NR NR
Retinal detachment IVT1: n=2; IVT4: n=4; L: n=2 NR NR None NR
Retinal vein occlusion IVT1: n=1; IVT4: n=2; L: n=3 NR NR NR NR
Retinal artery occlusion IVT1: n=0; IVT4: n=0; L: n=1 NR NR NR NR
Anterior ischemic optic
neuropathy
IVT1: n=1; IVT4: n=0; L: n=0 NR NR NR NR
Vitrectomy IVT1: n=26; IVT4: n=19; L:
n=31
NR NR NR NR
Open angle glaucoma IVT1: n=2; IVT4: n=7; L: n=2 NR NR NR NR
Glaucoma filtering
surgery
IVT1: n=0; IVT4: n=2; L: n=0 NR NR NR NR
Laser trabeculoplasty IVT1: n=0; IVT4: n=1; L: n=0 IVT: n=2; C: n=0 IVTL: n=1 NR NR
Ciliary body destruction IVT1: n=0; IVT4: n=1; L: n=0 NR NR NR NR
Continued
44
Ford
JA,Lois
N,Royle
P,etal.BM
J
Open
2013;3:e002269.doi:10.1136/bm
jopen-2012-002269
C
u
rre
n
t
tre
a
tm
e
n
ts
in
d
ia
b
e
tic
m
a
c
u
la
r
o
e
d
e
m
a
group.bmj.com
 o
n
 June 12, 2017 - Published by 
http://bmjopen.bmj.com/
D
ow
nloaded from
 
Table 15 Continued
DRCR Network 2008
(Ip et al/Beck et al/
Bressler et al) 22 61 63 64
Gillies et al/Sutter
et al32 136–138 Gillies et al33
Kim
et al45 Lam et al34
Ockrim et al/
Sivaprasad et al42 62
Endophthalmitis IVT1: n=0; IVT4: n=;0 L: n=0 (Infectious) IVT: n=1;
C: NR
(Culture-negative) IVTL:
n=1
None (sterile) IVT: n=1
Pseudoendophthalmitis IVT1: n=0; IVT4: n=;0 L: n=0 NR NR NR NR
Chemosis NR NR NR NR NR
Percentage of increase
in cataract scores
NR NR NR IVT:+1.0 SD1.1
(p=NS vs L);
IVTL:+1.3 SD1.9
(p=NS vs L); L:
+0.5 SD0.9
NR
Ocular hypertension
(>21 mm Hg)
NR NR NR NR NR
Cataract progression NR NR Phakic eyes, progression
by ≥2 AREDS grade,
IVTL: 64% (p<0.001); L:
11% (p<0.001)
NR NR
Corneal
decompensation
NR IVT: NR; C: n=1 NR NR NR
Cataract surgery NR NR IVTL: 61% (p<0.001); L:
0%
NR IVT: n=2; L: n=1
Vitreous haemorrhage NR NR NR IVTL: n=1
Lens opacity NR NR NR NR Significantly greater
change in lens opacity in
IVT group than in L group
(1.9)
Deaths N=33, unrelated to study
treatment
IVT: n=1; C: n=2 IVTL: n=2; L: n=1 NR NR
CPL, control plus laser; IOP, intraocular pressure; NR, not reported; IVT, intravitreal triamcinolone; IVTL, intravitreal triamcinolone plus laser; RDL, ranibizumab plus deferred laser;
RPL, ranibizumab plus laser; TPL, triamcinoloine plus laser.
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Table 16 Safety data in trials assessing more than one drug
Ahmadieh31
ATEMD 2011
(Oliveira
Neto et al)56
DRCR Network 2010
(Elman et al, )21 46
Lim
et al55 Soheilian et al37 41
Number of patients
Ocular adverse events
Mild anterior chamber
reaction
IVB: 19.5% (n=8 eyes), resolved
after 1 week of no treatment; IVB/
IVT: 18.9% (n=7 eyes), resolved
after 1 week of no treatment
NR NR NR IVB: 20% (n=10 eyes), resolved
after 1 week; IVB/IVT: 18%
(n=9 eyes), resolved after
1 week
Marked anterior chamber
reaction
IVB: n=1 (topical corticosteroid and
cycloplegic drops)
NR NR NR IVB: n=1 (topical corticosteroids
and cycloplegic drops);
Progression of fibrous
proliferation
IVB: n=1 with no sign of retinal
traction
NR NR NR IVB: n=1 with no sign of retinal
traction;
Vitreous haemorrhage IVB/IVT: n=1 after third injection
(excluded from study)
NR NR NR NR
IOP rise IVB: 23, 22 and 28 mm Hg at 6, 12
and 18 weeks (anti-glaucoma
drops)
NR IOP elevation more frequent with
triamcinolone + PL
IVB/
IVT:
8.3%
IVT:
10.8%
NR
IOP ≥10 mm Hg from
baseline
NR NR CPL: n=16; RPL: n=10; RDL: n=5;
TPL: n=70
NR NR
IOP ≥30 mm Hg from
baseline
NR NR CPL: n=3; RPL: n=2; RDL: n=4; TPL:
n=46
NR NR
Initiation of IOP lowering
treatment at any visit
NR NR CPL: n=9; RPL: n=5; RDL: n=4; TPL:
n=41
NR NR
Iris neovascularisation None NR NR NR NR
Lens opactiy None NR NR NR Severe lens opacity IVB/IVT:
n=4 eyes; MPC: n=1 eye
Endophthalmitis NR NR CPL: n=1; RPL: n=1; RDL: n=1; TPL:
n=0
NR None
Pseudoendophthalmitis NR NR CPL: n=1; RPL: n=0; RDL: n=0; TPL:
n=1
NR NR
Ocular vascular event NR NR CPL: n=1; RPL: n=1; RDL: n=0; TPL:
n=2
NR NR
Retinal detachment NR NR CPL: n=0; RPL: n=0; RDL: n=1; TPL:
n=0
NR None
Vitrectomy NR NR CPL: n=7; RPL: n=0; RDL: n=3; TPL:
n=0
NR NR
Vitreous haemorrhage NR NR CPL: n=15; RPL: n=3; RDL: n=4; TPL:
n=2
NR None
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Table 16 Continued
Ahmadieh31
ATEMD 2011
(Oliveira
Neto et al)56
DRCR Network 2010
(Elman et al, )21 46
Lim
et al55 Soheilian et al37 41
Cataract surgery NR NR CPL: n=11 (of those phakic at
baseline); RPL: n=6 (of those phakic at
baseline); RDL: n=8 (of those phakic at
baseline); TPL: n=19 (of those phakic
at baseline)
NR NR
Glaucoma surgery NR NR NR NR NR
Retinal
neovascularisation
NR NR NR NR IVB: n=4 (all resolved); MPC:
n=3 eyes (2 resolved)
Development of early
PDR
NR NR NR NR IVB: n=1; IVB/IVT: n=4; MPC:
n=3
Progression to high-risk
PDR
NR NR NR NR IVB: n=4; IVB/IVT: n=3; MP:
n=3
Ocular hypertension
(≥23 mm HG)
NR NR NR NR IVB/IVT: 16% (n=8 of eyes),
controlled medically in all
except 1 that progressed to
neovascular glaucoma
Systemic adverse events
Acute myocardial
infarction
N=1, considered
not to be related to
the study drug
No specific systemic adverse events
that could be attributed to chance
No significant blood pressure
increase, no thromboembolic
events
Deaths C: n=1 N=1, considered
not to be related to
the study drug
CPL: n=8; RPL: n=5; RDL: n=3; TPL:
n=2
IVB/IVT: n=2; MPC: n=2
C, control; CPL, control plus laser; DMO, diabetic macular oedema; IOP, intraocular pressure; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; IVRL, intravitreal ranibizumab plus
laser; IVT, intravitreal triamcinolone; L, laser; NR, not reported; PDR, proliferative diabetic retinopathy; RDL, ranibizumab plus deferred laser; RPL, ranibizumab plus laser; TPL, triamcinoloine
plus laser.
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statistically signiﬁcant difference between laser and
triamcinolone at 6 months (triamcinolone type not
reported). When these two trials were pooled through
meta-analysis, the treatment effect favoured laser but the
differences were not statistically signiﬁcant (ﬁgure 6).
Ockrim et al62 (n=88) compared 4 mg intravitreal triam-
cinolone (Kenalog) with laser alone. At 12 months, they
found no statistically signiﬁcant BCVA improvement
between the triamcinolone and laser groups. Gillies
et al32 (n=69) compared 4 mg of triamcinolone
(Kenacort) with sham injection. Mean BCVA improved
statistically signiﬁcantly with triamcinolone at 24 months
compared with sham injection (3.1 letter gain compared
with 2.9 letter loss, p=0.01).
Figure 2 Ranibizumab 0.5 mg alone versus laser alone. (A) Mean change in best corrected visual acuity. (B) Proportion with
>15 letter gain. (C) central macular thickness.
Figure 3 Ranibizumab 0.5 mg plus laser versus ranibizumab 0.5 mg alone. (A) Mean change in best corrected visual acuity.
(B) Proportion with >15 letter gain. (C) central macular thickness.
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Lam et al34 (n=111) compared triamcinolone 4 mg
alone with 4 mg of triamcinolone plus laser or laser
alone. At 6 months, the authors found no difference in
BCVA between any of the groups. Elman et al21 (n=854)
compared 4 mg of triamcinolone (Trivaris) plus laser
with ranibizumab plus prompt (within 3–10 days) or
deferred (more than 24 week) laser and laser alone. At
2 years, they found a statistically signiﬁcant difference in
mean BCVA between ranibizumab plus prompt/
deferred laser compared with laser alone (7 letter gain/
9 letter gain compared with 3 letter gain), but no
difference with triamcinolone plus laser compared with
laser alone (2 letter gain compared with 3 letter gain).
Neto et al56 (n=120) compared 4 mg triamcinolone
alone (triamcinolone type not reported) with 4 plus
1.25 mg bevacizumab. At 6 months, they found no statis-
tically signiﬁcant difference between groups.
The Elman and Lam studies were suitable for
meta-analysis, which showed non-statistically signiﬁcant
improvements in mean BCVA and the proportions of
patients with more or equal than 15 letter gain in the
triamcinolone plus laser group compared with laser
alone (ﬁgure 7).
Adverse events are shown in tables 15 and 16.
Triamcinolone was associated with consistently higher
incidences of IOP increase and cataracts. Gilles and col-
leagues reported a cataract rate of over 50% by 3 years
in patients treated with triamcinolone.
Other pertinent studies
Only one study in abstract form directly compared beva-
cizumab with ranibizumab.51 Bevacizumab and ranibizu-
mab have been compared through an indirect
comparison of ﬁve trials.65 There was no evidence of a
difference between the drugs; however, wide credible
intervals meant that the superiority of either drug could
not be excluded.
Two-year results of the CATT (Comparison of AMD
Treatment Trials) and 1 year results of the IVAN (Inhibit
VEGF in Age-related choroidal Neovascularisation),
recently published, have demonstrated a good safety
proﬁle of anti-VEGF therapies when used to treat
patients with age-related macular degeneration.66 67 The
CATT study randomised 1208 patients with AMD to
monthly or as required injection of either ranibizumab
or bevacizumab. At 1 year, the mean BCVA was similar in
Figure 4 Ranibizumab 0.5 mg plus laser versus laser alone. (A) Mean change in best corrected visual acuity. (B) Proportion
with >15 letter gain. (C) Central macular thickness.
Figure 5 Pegaptanib 0.3 mg versus sham injection. (A) Proportion with >15 letter gain.
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both groups (8 letter gain in bevacizumab and 8.5 in
ranibizumab). Over 2 years, the rates of deaths, myocar-
dial infarction and stroke did not differ between the
ranibizumab and bevacizumab treatment groups.
However, there was a higher rate of serious adverse
events in the bevacizumab group compared with
the ranibizumab group. This increased event rate was
driven mainly by hospitalisations (RR 1.29, 95% CI
1.01 to 1.66). However, the hospitalisations were not
caused by known adverse events of bevacizumab.
Arteriothrombotic events and heart failure occurred in
less than 2% of participants in the IVAN, and they were
more often observed in the ranibizumab group than in
the bevacizumab group (p=0.03). Further data from
other ongoing clinical trials may provide more insight
on the safety or anti-VEGF treatment and possible differ-
ences on this respect among available drugs.
Campbell et al68 conducted a population-based nested
case–control study of 91 378 older adults with a history
of physician-diagnosed retinal disease. The authors
found that neither ranibizumab nor bevacizumab was
associated with signiﬁcant risks of ischaemic stroke,
acute myocardial infarction, congestive heart failure or
venous thromboembolism.
A recent systematic review speciﬁcally assessing adverse
events in anti-VEGF drugs found a low incidence of
serious (below 1 in 100) and non-serious ocular events
(below 1 in 500) from ranibizumab, bevacizumab and
pegaptanib.69
Fung et al70 used an internet-based survey of clinicians
to assess the safety of bevacizumab. The survey covered
over 5000 patients and found that bevacizumab was asso-
ciated with an infrequent incidence of adverse events
(all less than 0.21%).
One study, which assessed diclofenac, did not meet
the inclusion criteria (follow-up for only 12 weeks).71
The authors randomised 32 patients to either intravitreal
diclofenac or triamcinolone and found that both diclo-
fenac and triamcinolone reduced CMT, but a statistically
signiﬁcant visual improvement was observed only in the
triamcinolone group.
Sﬁkakis et al72 undertook a 30-week randomised cross-
over trial comparing inﬂiximab and placebo. The study
failed to meet our inclusion criteria (only 11 patients
included). The authors found that inﬂiximab resulted in
a 28.6% improvement in vision compared with 4.3%
with placebo. The improvement seen with placebo could
be due to a ‘carry over effect’, seen in cross-over trials.
The Fenoﬁbrate Intervention and Event Lowering in
Diabetes (FIELD) trial was primarily a study to see if the
lipid-lowering agent fenoﬁbrate could reduce macrovas-
cular and microvascular events in type 2 diabetes.73
Figure 7 Triamcinolone 4 mg plus laser versus laser alone. (A) Mean change in best corrected visual acuity. (B) Proportion with
>15 letter gain.
Figure 6 Triamcinolone 4 mg versus laser alone. (A) Mean change in best corrected visual acuity. (B) Proportion with >15 letter
gain.
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However, a substudy within FIELD recruited 1012
patients to a retinopathy study. The primary outcome in
the main study was need for laser therapy (3.4% on
fenoﬁbrate vs 4.9% on placebo), but the substudy used
retinal photography to assess progression of retinopathy
or development of macular oedema. The HR at 6 years
for DMO was 0.69 (95% CI 0.54 to 0.87) in the fenoﬁ-
brate group compared to placebo.
Ruboxistaurin is another oral agent which has been
assessed for the treatment of DMO. Aiello and collea-
gues randomised 686 patients to receive placebo or one
of three doses of ruboxistaurin.74 75 There was no statis-
tically signiﬁcant difference in delay to sight-threatening
DMO in any ruboxistaurin group compared to placebo.
The authors suggest that differences in laser treatment
between groups may have contributed to the non-
signiﬁcant ﬁnding.
Assessment of heterogeneity within meta-analysis
Heterogeneity was assessed methodologically and statistic-
ally. Methodological heterogeneity was assessed by compar-
ing the study population, interventions, outcome measures
and follow-up. Studies that were not methodologically com-
parable were excluded from the meta-analysis. For
example, bevacizumab trials were not pooled because
Soheilian et al37 included patients who were laser naïve and
Ahmadieh et al31 included patients who were unresponsive
to laser. Some analyses were also excluded because sufﬁ-
cient details were not reported in the studies. For example,
several studies failed to report SDs.35 39
Statistical heterogeneity was assessed through I2 scores.
High statistical heterogeneity was found in two analyses
(2.3 and 4.3). Therefore, these results should be inter-
preted with due caution. Moderate heterogeneity was
found in three analyses (2.2, 3.1 and 3.2). Low heterogen-
eity was found in the remaining eight analyses.
Ongoing trials
There are numerous ongoing studies listed in appendix 2.
The most salient studies include a study to compare rani-
bizumab and bevacizumab (Schmidt-Erfurth), a study
investigating rescue ranibizumab treatment for patients
who have failed on bevacizumab (Chaudhry), a study
evaluating two algorithms for ranibizumab, ‘treat and
extend’ and ‘as required’ (RETAIN), further studies of
Trap-eye (VIVID and VISTA) and trials which are examin-
ing the use of NSAIDs, such as diclofenac and nepafenac
(NEVANAC and Soheilian).
DISCUSSION
It appears that anti-VEGF treatment is effective in DMO,
especially ranibizumab and bevacizumab. Meta-analysis
of available short-term data (up to 2 years) suggests that
ranibizumab is superior to laser and that adding laser
to ranibizumab treatment does not confer additional
beneﬁt. Steroid treatment has demonstrated mixed
success and, almost uniformly, increased the incidence
of cataracts and IOP. The licence for ﬂuocinolone takes
note of this and it is positioned as a treatment when
others have failed.
Strengths and limitations of the review
There are a number of strengths of this review. A robust
systematic review methodology was used. Reliability was
improved by excluding trials with small sample sizes or
short follow-up. Since a number of trials included similar
intervention arms, consistent treatment effects further
improve reliability. Validity was improved by assessing the
quality of trials using the Cochrane risk of bias tables.
Including abstracts from ARVO provided up-to-date
results. Pooling results through meta-analysis provided
further evidence. The random effects model was used
throughout to allow for heterogeneity among studies.
This review, however, has limitations. Although the inclu-
sion of abstracts provides more up-to-date results, the
studies contained in these abstracts could not be assessed
for risk of bias and should therefore be interpreted with
caution. In addition, reporting of quality assessment cri-
teria was variable. Allocation concealment was especially
poorly reported. There was only one study which compared
different anti-VEGFs51 and none that compared steroids
(ﬂuocinolone vs dexamethasone vs triamcinolone).
Therefore, it is difﬁcult to assess the effectiveness within
drug classes. As with any meta-analysis, questions of hetero-
geneity arise. Follow-up periods varied among studies.
A difference of 6 months was allowed for studies to be
pooled for meta-analysis, but this could have still resulted
in heterogeneity. High statistical heterogeneity was found
in a quarter of the analyses. Furthermore, because of the
low number of trials included, publication bias could not
be assessed by funnel plot analysis. The manufacturers
funded most of the trials for ranibizumab, pegaptanib,
dexamethasone and ﬂuocinolone, whereas trials for
bevacizumab and triamcinolone were generally funded by
non-pharmaceutical organisations. Generally, the non-
commercial studies had smaller numbers, perhaps because
of the funding restraints.
It is important to note that there may be differences
in laser treatment protocol between studies. This applies
to trials which combine drug treatments with laser or
include laser as a comparator. All studies referred to the
ETDRS protocol19 20 or a modiﬁed version of it. In the
ETDRS, once a diagnosis of clinically signiﬁcant macular
oedema was made, an angiogram was obtained to identi-
ﬁed ‘treatable lesions’. ‘Treatable lesions’ included dis-
crete points of retinal hyperﬂuorescence or leakage
(most of these are often microaneurysms), areas of
diffuse leakage within the retina related to microaneur-
ysms, intraretinal microvascular abnormalities, diffusely
leaking retinal capillary bed and retinal avascular zones.
In the ETDRS protocol, treatment of lesions closer than
500 microns from the centre of the macula was not
required initially; however, if vision was less than 20/40
and the oedema and leakage persisted, treatment up to
300 microns from the centre of the macula was
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recommended unless there was capillary dropout; in the
latter case, treatment was not recommended as it may
lead to further loss of perifoveal capillaries.
However, in routine clinical practice, clinicians gener-
ally use lighter and less intense treatment than speciﬁed
in the ETDRS protocol.76 In addition, some centres do
not use ﬂuorescein angiography (unlike the ETDRS
study19) to guide treatment. The exact adherence to the
ETDRS protocol within studies is unclear. For example,
in the BOLT study, a modiﬁed ETDRS protocol was
used. One of the aims of the protocol was ‘not darken-
ing/whitening of microaneurysms’, which is not consist-
ent with the ETDRS protocol.
Interpretation of the results
The anti-VEGF drugs appear to be clinically effective
in treating DMO in short-term studies (up to 2 years).
Ranibizumab has the most robust evidence base and has
shown superiority compared to laser and sham injection
in all trials and meta-analyses, except for the proportion
of patients with 10 or more letter gain in the DRCR.net
study published by Elman et al46 at 2 years follow-up.
Adding laser to ranibizumab conferred no beneﬁt.
Bevacizumab has also been shown to be superior to
laser. Three doses have been used (1.25, 1.5 and 2.5).
The higher dose does not appear to add further beneﬁt,
and most studies in the literature use 1.25 mg. The add-
ition of triamcinolone to bevacizumab did not provide
further beneﬁts. Pegaptanib has only been compared
to sham injection. Mean change in BCVA favoured
pegaptanib, but only through meta-analysis did the
proportion of patients with more than 15 letter gain
favour pegaptanib. Further published data are required
before drawing conclusions on aﬂibercept. However,
although the anti-VEGF drugs are a signiﬁcant advance,
they fail to improve BCVA by 10 or more letters in half
or more patients, and so they do not provide a complete
answer to DMO.
Steroid treatments have inconsistent results and are
undoubtedly associated with increased IOP and cataract.
The effects of dexamethasone appear to peak at
3 months. At 6 months, there was no signiﬁcant differ-
ence compared with laser. This might imply that earlier
retreatment is needed if the beneﬁcial effect is to be
maintained, but increasing the number of treatments
would very likely increase the associated complications,
especially with the relatively large needle size. The add-
ition of laser did not appear to add further beneﬁt.
There was no signiﬁcant difference in cataract formation
at 6 months with dexamethasone compared to observa-
tion, but it is likely that a higher incidence of cataracts
would be seen with longer follow-up. Signiﬁcantly more
patients suffered increased IOP in the dexamethasone
group compared with observation. Fluocinolone has
been shown to be effective compared with sham injec-
tion (FAME);29 60 however, when compared to standard
of care (laser or observation at clinician’s discretion),
there was no signiﬁcant difference in the proportion of
patients with a 15 letter or more gain. Both studies
reported higher incidence of cataract formation in the
ﬂuocinolone group, with over 80% at 3 years at the
higher dose. Results for triamcinolone are inconsistent.
Ip et al61 found that laser was more effective, while
others have found no statistically signiﬁcant difference.
Triamcinolone combined with laser, however, seemed to
have similar efﬁcacy as ranibizumab combined with laser
in pseudophakic eyes.21 46 Triamcinolone is more effect-
ive than sham injection. Triamcinolone has consistently
been associated with increased incidence of cataract and
raised IOP.
Steroids and laser therapy may affect CMT in a differ-
ent manner from anti-VEGF drugs. For example, when
ranibizumab alone is compared with ranibizumab plus
laser, it appears to be more effective in terms of mean
change in BCVA and proportion of patients with more
than 15 letter gain. However, ranibizumab plus laser is
more effective at reducing CMT. Furthermore, when
triamcinolone plus laser is compared with ranibizumab
plus laser, the latter appears to be more effective in
terms of change in BCVA and proportion of patients
with more than 15 letter gain, but triamcinolone plus
laser is more effective at reducing CMT. The reasons for
this are unclear. There is a weak correlation between
CMT and BCVA. However, the long-term beneﬁts of
reducing CMT are currently unknown.
No large observational studies were identiﬁed that
compared anti-VEGF drugs. Using an internet-based
survey, Fung et al70 found the incidence of adverse events
in bevacizumab to be low. One small outbreak of sterile
endophthalmitis was reported with a single batch of beva-
cizumab in Canada, emphasising the need for sterility
when preparing aliquots.77 Curtis et al78 carried out a very
large retrospective cohort study in 146 942 patients aged
65 and over with age-related macular degeneration
(AMD). Their aim was to examine cardiovascular out-
comes in patients treated with the four options: photo-
dynamic therapy (PDT), pegaptanib, bevacizumab and
ranibizumab. The authors reported that one of their
comparisons showed an increase in overall mortality and
stroke risk with bevacizumab compared to ranibizumab,
with HRs of 0.86 (95% CI 0.75 to 0.98) and 0.78 (0.64 to
0.96), respectively. However, owing to the very large cost
differences between bevacizumab and ranibizumab, the
authors noted that selection bias might be operating,
with poorer people (with poorer health) more likely to
be treated with bevacizumab. They therefore carried out
another analysis using only ophthalmological clinics
which used only one drug, to avoid selection bias. This
analysis showed no signiﬁcant difference: overall mortal-
ity HR for ranibizumab 1.10 (95% CI 0.85 to 1.141); MI
0.87 (0.53 to 1.14); stroke 0.87 (0.61 to 1.24).
Gower et al79 analysed 77 886 anti-VEGF injections
from Medicare data (46% ranibizumab and 54% bevaci-
zumab). Results have only been published in abstract
form. The authors found an increased risk of overall
mortality and cerebrovascular events in the bevacizumab
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group (HR 1.11 99% CI 1.01 to 1.23 and 1.57, 1.04 to
2.37, respectively). There was no statistically signiﬁcantly
increased risk in the ranibizumab group. The authors
acknowledge that a limitation of the study is a failure to
adjust for important confounding factors (such as
smoking, hypertension and hyperlipidaemia).
Considering the cost difference, it is likely that patients
treated with bevacizumab would have been in a lower
socioeconomic class and therefore at high risk of mortal-
ity and vascular disease.
Implications for clinicians
The anti-VEGF drugs appear to be a signiﬁcant advance
in the treatment of DMO and are regarded now as the
treatment of choice for patients affected by this condi-
tion. Studies assessing the effectiveness of steroids have
reported mixed results. The high rates of cataract and
increased IOP are a drawback. Triamcinolone combined
with laser may be a good option for pseudophakic
patients and may be more cost-effective than treatment
with ranibizumab. However, the need for fewer adminis-
trations, potentially one every 3 years with ﬂuocinolone,
is advantageous. From an administration perspective,
some patients might prefer infrequent steroid injections
with a sizeable risk of cataract, and a small, but existent,
risk of glaucoma, to frequent anti-VEGF injections, even
if the potential gain may not be fully comparable.
Steroids may also be considered for patients who do not
adequately respond to anti-VEGFs. Currently, the role of
laser in the treatment of DMO is debatable. Short-term
data from available trials have demonstrated the super-
iority of anti-VEGF with regard to laser treatment but
have failed to demonstrate a beneﬁt of combining both
treatment approaches. It is possible that some ophthal-
mologists may still opt to offer laser treatment to patients
with very focal areas of leakage.
Currently, there is more evidence for the effectiveness
of ranibizumab and bevacizumab than for pegaptanib
and VEGF-trap eye. The results of direct head to head
trials of ranibizumab and bevacizumab are awaited.
Bevacizumab is not licensed for intraocular use but costs
considerably less than other forms of therapy.
Ranibizumab is licensed and more expensive, but its use
is supported by large manufacturer-funded trials demon-
strating its clinical effectiveness. In the UK, the General
Medical Council recommends that unlicensed medica-
tions should only be prescribed if ‘an alternative,
licensed medicine would not meet the patient’s needs’
and there is ‘a sufﬁcient evidence base and/or experi-
ence of using the medication to demonstrate its safety
and efﬁcacy’.80 The FDA says that when using a drug
‘off-label’, clinicians ‘have the responsibility to be well
informed about the product, to base its use on ﬁrm sci-
entiﬁc rationale and on sounded medical evidence, and
to maintain records of the product’s use and effects’.81
Patients should be fully aware of the use of any
unlicensed medication and consent to any safety or efﬁ-
cacy uncertainties.
The place of intravitreal steroids needs consideration
now that we have the anti-VEGFs drugs, as does the role
of laser. The anti-VEGFs drugs may now be the ﬁrst-line
treatment in place of laser, with laser being used select-
ively for focal lesions, and in sequence after anti-VEGF
therapy once the retinal thickness has been reduced.
However, it should be noted that about half of the
patients do not get good results with anti-VEGFs. In
RESTORE, only 50% of patients had gains in VA of 10
or more letters. So the anti-VEGFs are ‘game-changers’,
but their impact should not be overestimated.
In those who do not respond to anti-VEGFs or laser,
there remains a place for steroids, despite their high
adverse effect rates. The European licence for ﬂuocino-
lone recognises this, by stating that it should be used
when other therapies have not had sufﬁcient effect.82
The commonest adverse effect is cataract, but that is
very common in people with diabetes, and many are
already pseudophakic when treatment of DMO is
required.
Vitreoretinal surgery for the treatment of DMO was
not included in our review. Laidlaw reviewed the litera-
ture and only found evidence for vitrectomy when there
were signs of clinical or OCT traction.83 However, even
in these cases, the evidence was not strong.
Implications for policy makers
In the UK, the National Institute of Health and Clinical
Excellence (NICE) has recently made the decision not
to recommend ranibizumab for the treatment of
DMO.84 NICE concluded that ranibizumab, although
clinically effective, was not cost-effective compared to
laser therapy. Bevacizumab is less than a tenth of the
cost of ranibizumab but is unlikely to be licensed. This
beckons the question as to whether policy makers
should recommend cheaper unlicensed medications
over a more expensive licensed alternative when their
efﬁcacy and side effects appear to be similar.
Unanswered questions
Several unanswered questions remain. Studies evaluating
the effectiveness of ranibizumab compared with bevaci-
zumab are needed. Although the anti-VEGFs are clinic-
ally effective and a major step forward in the
management of DMO, it has to be noted that they have
little effect in a large number of patients. Generally
speaking, the proportion of patients who have demon-
strated 10 or more letter gain using anti-VEGFs is
between 30% to 50% in the trials that demonstrate the
greatest effectiveness. Most of these patients would not
achieve the 20/40 visual acuity required for driving.
More effective treatments, or combinations of treat-
ments, are required.
There is a lack of speciﬁc evidence for the use of
anti-VEGF drugs or steroids in patients with macular
ischaemia secondary to DMO. A number of trials
excluded patients with macular ischaemia.23 34 35 40 53 62
The RESTORE trial included patients with macular
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ischaemia and undertook a subgroup analysis.24 The
authors compared patients with (n=34) and without
(n=35) macular ischaemia at baseline. They found that
those without macular ischaemia responded better to
ranibizumab (mean average change in BCVA at
12 months 7.2 letters gain compared with 6.3 letters).
Larger trials are needed to assess the use of anti-VEGF
drugs and steroids in patients with macular ischaemia.
The duration of treatment is as yet uncertain. Most of
the included studies use a retreatment protocol based on
clinical need or OCT results. For example, in the BOLT
study, patients received a median of nine injections of
bevacizumab over 24 months.23 85 However, it is not yet
known for how frequent long-term maintenance injec-
tions will be needed and whether laser treatment in
sequence could potentially reduce the number of
anti-VEGF injections required. Other treatment strategies
to apply laser, such as using laser power at subthreshold
levels, may prove more effective.86 Future trials should
use active comparators which are used in routine clinical
practice and avoid placebo-controlled trials.
CONCLUSION
This review evaluated current treatments for DMO.
Undoubtedly, the use of anti-VEGFs heralds a new era for
patients who suffer from DMO. Currently, the anti-VEGFs
ranibizumab and bevacizumab have consistently shown
good clinical effectiveness without major unwanted side
effects. Steroid results have been mixed and are usually
associated with cataract formation and IOP increase. Based
on the short-term data available, adding laser therapy to
anti-VEGFs does not appear to confer additional beneﬁt.
Despite the current wider spectrum of treatments for
DMO, only a small proportion of patients recover good
vision (≥20/40), and thus the search for new therapies
to prevent and manage DMO needs to be continued.
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APPENDIX 1: METHODS OF THE LITERATURE SEARCH
Searches for clinical trials
Ovid MEDLINE 1948-week 2 July 2012 and Ovid MEDLINE(R)
In-Process and Other Non-Indexed Citations 11 July 2012
1. Diabetic Retinopathy/dt (Drug Therapy)
2. Macular Edema/dt (Drug Therapy)
3. (diabet* adj2 macular adj (edema or oedema)).tw.
4. (diabet* adj2 maculopathy).tw.
5. (diabet* adj2 retinopathy).tw.
6. 1 or 2 or 3 or 4 or 5
7. (ranibizumab or lucentis or bevacizumab or avastin or pegaptanib
or macugen or aflibercept or vegf trap-eye or steroid* or cortico-
steroid* or dexamethasone or fluocinolone or triamcinolone or
anti-VEGF* or anti-vascular endothelial growth factor*).tw.
8. exp Vascular Endothelial Growth Factor A/
9. exp Fluocinolone Acetonide/
10. exp Triamcinolone/
11. 7 or 8 or 9 or 10
12. 6 and 11
13. randomised controlled trial.pt.
14. controlled clinical trial.pt.
15. (masked or sham or placebo or control group or random*).tw.
16. 13 or 14 or 15
17. 12 and 16
18. (case reports or editorial or letter or review).pt.
19. 17 not 18
20. limit 19 to humans
EMBASE 1947–2012 week 27
1. (ranibizumab or lucentis or bevacizumab or avastin or pegaptanib
or macugen or aflibercept or vegf trap-eye or dexamethasone or
fluocinolone or triamcinolone or anti-VEGF* or anti-vascular endo-
thelial growth factor*).m_titl.
2. (diabetic macular edema or diabetic macular oedema or diabetic
retinopathy or diabetic maculopathy).m_titl.
3. 1 and 2
4. random*.tw.
5. 3 and 4
Cochrane Central Register of Controlled Trials, Issue 7 of 12, July 2012
Ranibizumab or lucentis or bevacizumab or avastin or pegaptanib
or macugen or aflibercept or vegf trap-eye or steroid* or corticosteroid*
or dexamethasone or fluocinolone or triamcinolone or anti-VEGF* or
anti-vascular endothelial growth factor* in Record Title and diabetic
macular edema or diabetic macular oedema or diabetic retinopathy or
diabetic maculopathy in Record Title
Web of Science—with Conference Proceedings (updated 12 July 2012)
Title=(ranibizumab or lucentis or bevacizumab or avastin or pegap-
tanib or macugen or aflibercept or vegf trap-eye or steroid* or
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corticosteroid* or dexamethasone or fluocinolone or triamcinolone or
anti-VEGF* or anti-vascular endothelial growth factor*) AND Title=(dia-
betic macular edema or diabetic macular oedema or diabetic retinop-
athy or diabetic maculopathy) AND Title=(random*)
Searches for systematic reviews
Ovid MEDLINE(R) Daily Update 11 July 2012, Ovid MEDLINE(R)
In-Process and Other Non-Indexed Citations 11 July 2012
1. Diabetic Retinopathy/dt (Drug Therapy)
2. Macular Edema/dt (Drug Therapy)
3. (diabet* adj2 macular adj (edema or oedema)).tw.
4. (diabet* adj2 maculopathy).tw.
5. (diabet* adj2 retinopathy).tw.
6. 1 or 2 or 3 or 4 or 5
7. (ranibizumab or lucentis or bevacizumab or avastin or pegaptanib
or macugen or aflibercept or vegf trap-eye or steroid* or cortico-
steroid* or dexamethasone or fluocinolone or triamcinolone or
anti-VEGF* or anti-vascular endothelial growth factor*).tw.
8. exp Vascular Endothelial Growth Factor A/
9. exp Fluocinolone Acetonide/
10. exp Triamcinolone/
11. 7 or 8 or 9 or 10
12. 6 and 11
13. (systematic review or meta-analysis or pubmed or medline).tw.
14. meta-analysis.pt.
15. cochrane.af.
16. 13 or 14 or 15
17. 12 and 16
Cochrane Database of Systematic Reviews and Technology Assessments
Database, Cochrane Library July Issue, 2012
Ranibizumab or lucentis or bevacizumab or avastin or pegaptanib
or macugen or aflibercept or vegf trap-eye or steroid* or corticosteroid*
or dexamethasone or fluocinolone or triamcinolone or anti-VEGF* or
anti-vascular endothelial growth factor* in Record Title and diabetic
macular edema or diabetic macular oedema or diabetic retinopathy or
diabetic maculopathy in Record Title
Searches for safety and adverse events
Ovid MEDLINE(R) Daily Update 11 July 2012, Ovid MEDLINE(R)
In-Process and Other Non-Indexed Citations 11 July 2012 ; EMBASE
1980–2012 week 27
1. (ranibizumab or lucentis or bevacizumab or avastin or pegaptanib
or aflibercept or vegf trap-eye or macugen or dexamethasone or
fluocinolone or triamcinolone or anti-VEGF* or anti-vascular endo-
thelial growth factor*).m_titl.
2. (diabetic macular edema or diabetic macular oedema or diabetic
retinopathy or diabetic maculopathy).m_titl.
3. 1 and 2
4. (risk or safety or adverse or harm or pharmacovigilance).tw.
5. (side-effect* or precaution* or warning* or contraindication$ or
contra-indication* or tolerability or toxic*).tw.
6. 4 or 5
7. 3 and 6
Searches of the annual meeting abstracts (for trials,
reviews and safety studies)
▸ ARVO (Association for Research in Vision and Ophthalmology)
(2002–2012)
▸ ADA (American Diabetes Association) (2002–2012)
▸ EASD (European Association for the Study of Diabetes) (2002–
2012)
Other searches
Web sites of the following
▸ Drugs@FDA: FDA Approved Drug Products
▸ European Medicines Association
▸ ClinicalTrials.gov
▸ EU Clinical Trials Register
National Institute for Health and Clinical Excellence
APPENDIX 2: ONGOING TRIALS IN CLINICALTRIALS.GOV
▸ Schmidt-Erfurth and colleagues are comparing ranibizumab and
bevacizumab in DME (NCT00545870)
▸ TRIASTIN study is comparing ranibizumab, triamcinolone and
sham injection (NCT00682539)
▸ Maturi and colleagues are comparing bevacizumab plus dexa-
methasone with bevacizumab alone (NCT01309451)
▸ IBeTA study ( Jorge and colleagues) is comparing bevacizumab
(1.5 mg) plus laser, triamcinolone (4 mg) plus laser with laser
alone (NCT00997191)
▸ Chaudhry and colleagues are evaluating ranibizumab in patients
who have failed with 3–6 injections of bevacizumab
(NCT01253694)
▸ MIDME study (Pfizer) is comparing pegaptanib 0.3 mg with sham
injection (NCT01175070)
▸ Figueira and colleagues are comparing pegaptanib plus laser with
laser alone (NCT01281098)
▸ RESPOND (Novartis) is comparing ranibizumab (0.5 mg) alone
with ranibizumab plus laser or laser alone (NCT01135914)
▸ RETAIN (Novartis) study is comparing two different ranibizumab
algorithms; ‘treat and extend’ versus as needed (NCT01171976)
▸ RED-ES (Novartis) is comparing ranibizumab with laser in patients
with visual impairment due to DME (NCT00901186)
▸ READ 3 study (Do and colleagues) are comparing two doses of
ranibizumab 0.5 and 2 mg (NCT01077401)
▸ VIVID-DME and VISTA DME studies (Bayer) are comparing afliber-
cept with laser. (NCT01331681 and NCT01363440)
▸ Gillies and colleagues are comparing bevacizumab with dexa-
methasone (NCT01298076)
▸ Soheilian and colleagues are performing a phase I study looking at
the use of diclofenac compared with bevacizumab in DME
(NCT00999791)
▸ López-Miranda and colleagues are comparing the use of bevacizu-
mab before and after laser therapy (NCT00804206)
▸ NEVANAC study is comparing triamcinolone alone with triamcino-
lone plus nepafenac (NSAID) (NCT00780780)
▸ Elman and colleagues are comparing laser alone, laser combined
with an intravitreal injection of triamcinolone, laser combined with
an intravitreal injection of ranibizumab, or intravitreal injection of
ranibizumab alone (NCT00444600)
▸ BRDME (Schlingemann and collagues) study is comparing the use
of bevacizumab and ranibizumab in the treatment of patients with
DME (OCT central area thickness > 275 μm) (NCT01635790)
▸ Wiley and colleagues are comparing bevacizumab and ranibizu-
mab in patients with DME in at least one eye (NCT01610557)
▸ Protocol T study (Wells and colleagues) is comparing effectiveness
of a aflibercept, bevacizumab and ranibizumab for DME
(NCT01627249)
▸ Allergan-funded study comparing safety and efficacy of 700 µg
dexamethasone implant against 0.5 mg ranibizumab in patients
with DME (NCT01492400)
▸ Pfizer-funded study comparing effectiveness of 0.3 mg pegaptanib
against sham injection (NCT01100307)
▸ Allergan-funded study comparing safety and efficacy of an intravi-
treal dexamethasone implant (700 and 350 µg) against sham in
patients with DME (NCT00168389)
▸ Allergan-funded study comparing safety and efficacy of an intravi-
treal dexamethasone implant (700 and 350 µg) against sham in
patients with DME (NCT00168337)
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